



URI ELKAYAM, M.D.

University of Southern California
Keck School of Medicine
Division of Cardiology
2020 Zonal Avenue, IRD, Room 331
Los Angeles, CA 90033
Cell: (310) 709-6602
elkayam@usc.edu

Award-winning, highly-experienced Cardiologist in active clinical practice. 40+ years experience. Professor of Medicine – University of Southern California. Director of Maternal Cardiology at Los Angeles General Hospital. Performed thousands of cardiac catheterizations. Extensive experience managing heart failure and heart disease in pregnancy. Widely published author. Experienced expert witness.

ACADEMIC APPOINTMENTS

| | |
|--|--------------|
| University of Southern California, <i>Los Angeles, California</i> <u>Professor of Medicine</u> | 1989-present |
| University of Southern California, <i>Los Angeles, California</i> <u>Associate Professor of Medicine</u> | 1984-1989 |
| University of Southern California, <i>Los Angeles, California</i> <u>Assistant Professor of Medicine</u> | 1981-1984 |
| University of California, <i>Irvine, California</i> <u>Assistant Professor of Medicine</u> | 1979-1981 |

SPECIFIC CLINICAL AND TEACHING RESPONSIBILITIES

| | |
|---|--------------|
| Cardiac Care Unit, LAC - USC Medical Center <u>Attending Physician</u> | 1979-present |
| Cardiology Consultation Service LAC - USC Medical Center <u>Attending Physician</u> | 1979-present |

Cardiology Clinic LAC - USC Medical Center 1979-present
Attending Physician

Cardio Obstetrics Clinic, and LAC - USC Medical Center 1979-present
Attending Physician

SPECIFIC ADMINISTRATIVE RESPONSIBILITIES

LAC/USC Medical Center, Los Angeles, California 2009 - present
Director Maternal Cardiology

Heart Failure Program, USC School of Medicine, Los Angeles, California 1993 – 2009
Director

USC School of Medicine, Los Angeles, California 1991 – 1993
Acting Chief of Cardiology

USC University Hospital, Los Angeles, California 1990 – 1993
Chief of Cardiology

Los Angeles County-USC Medical Center, Los Angeles, California 1981-1991
Director, In-Patient Cardiology (ICCU, Cardiology Ward, Consult Service)

University of California, Irvine Medical Center, Los Angeles, California 1979-1981
Director, Coronary Care Unit

MILITARY SERVICE

Officer Israeli Defence Forces 1962 – 1965

EDUCATION

Mikveh-Israel, Chulon, Israel 1958-1962
High School Diploma

University of Vienna, Vienna, Austria 1966-1970
Degree

Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel 1970-1973
Degree

Tel Aviv Medical Center, Tel-Aviv, Israel 1973-1974
Rotating Internship

| | |
|---|-----------------|
| Ichilov Hospital, Sourasky Medical Center, Tel-Aviv, Israel <u>Internal Medicine Residency</u> | 1974-1976 |
| Hospital of Albert Einstein, College of Medicine, New York, New York <u>Cardiology Fellowship</u> | 1976-1978 |
| Cedars Sinai Medical Center, Los Angeles, California <u>Cardiology Fellowship</u> | 1978-1979 |
| Cedars Sinai Medical Center, Los Angeles, California <u>Sabbatical - Cardiac Transplantation Training</u> | 01/1996-02/1996 |
| Rush-Presbyterian - St. Luke's Medical Center, Chicago, Illinois <u>Sabbatical</u> | 03/1996-06/1996 |

LICENSURE

California, A-33649, 1978 ECFMG - Certificate No. 228-332-3 July 1974

BOARD CERTIFICATION

| | |
|---|----------------|
| Israeli Board of Cardiology | April 1989 |
| American Board of Internal Medicine | September 1989 |
| American Board of Internal Medicine, Cardiovascular Disease | November 1991 |
| American Board of Internal Medicine, Cardiovascular Disease | November 2009 |
| American Board of Internal Medicine, Advanced Heart Failure | November 2014 |
| National Board of Physicians and Surgeon's: | |
| Diplomat of Internal Medicine | 2024 |
| Diplomat of Cardiovascular Disease | 2024 |
| Diplomat of Advanced Heart Failure and Transplant | 2024 |

SOCIETY MEMBERSHIP

| | |
|---|------|
| American College of Chest Physicians, Fellow, | 1979 |
| American College of Physicians, Fellow | 1978 |
| American College of Cardiology, Fellow | 1977 |
| American Heart Association: | |
| Council on Arteriosclerosis, Thrombosis, and Vascular Biology, Fellow | 1999 |
| Council on Clinical Cardiology, Fellow | 2000 |
| Heart Failure Society of America, Fellow | 2017 |
| Heart Valve Society of America | |
| | 2008 |

COMMITTEES

American College of Cardiology Committee on Cardiovascular Disease in Women 2017-2021
American College of Cardiology Committee on Cardio Obstetrics

EDITORIAL BOARDS

Journal of the American College of Cardiology – Advances Associate Editor
Cardiology in Review
Journal of the American College of Cardiology Heart Failure - Advisor
Journal of Cardiovascular Pharmacology and Therapeutics
Cardiovascular Drug and Therapy
Preventive Cardiology (past)
The Journal of Cardiac Failure (past)
American Journal of Cardiology (past)
Cardiology (past)
Journal of the American College of Cardiology (past)

JOURNAL EDITORIAL REVIEWER

Annals of Internal Medicine
American Heart Journal
American Journal of Cardiology
American Journal of Obstetrics and Gynecology
Archives of Internal Medicine
Cardiology
Cardiovascular Drug and Therapy
Catheterization and Cardiovascular Diagnosis
Chest
Circulation
Circulation Heart Failure
European Heart Journal
European Journal of Heart Failure
Heart
International Journal of Cardiology
Journal of the American College of Cardiology (JACC)
JACC Heart Failure
JAMA Cardiology
Journal of Cardiac Failure
New England Journal of Medicine
Obstetrics and Gynecology
The Lancet

HONORS & AWARDS

| | |
|--|-----------|
| Melvin L Marcus Memorial Award–8th World Congress on Heart Failure <i>Distinguished Contribution as a Gifted Teacher</i> | 2002 |
| USC Women’s & Children’s Hospital Award for Education of Residents and Fellows <i>Department of Maternal – Fetal Medicine</i> | 2002 |
| 4th International Meeting on Interventional Cardiology, London, UK <i>Best Abstract Presentation</i> | 2001 |
| America's Top Doctors | 2001-2016 |
| Best Doctors in America | 2000–2016 |
| Southern California Super Doctors | 2007-2016 |
| International Academy of Cardiology <i>Distinguished Fellowship Award</i> | 2007 |
| University of Southern California | 2014 |
| Golden Apple Award for Teaching - Division of Cardiovascular Medicine | |
| Save a Heart Foundation <i>Lifetime Achievement Award</i> | 2016 |
| American College of Cardiology Bernadine Healy Leadership in Women's CV Disease <i>Distinguished Award</i> | 2021 |

CHAIRMANSHIPS

1. Chairman of a Symposium: "Vasodilator therapy: does it make a difference?" Fall Symposium, American Heart Association - Greater Los Angeles Affiliate. Los Angeles, California, September 1982.
2. Chairman of a Symposium: "Cardiac problems in pregnancy," 51st Annual Fall Symposium, American Heart Association - Greater Los Angeles Affiliate. Los Angeles, California, September 1983.
3. Chairman of a Symposium: "Pregnancy in the patients with cardiac disease," at the 33rd Annual Scientific Session of the American College of Cardiology. Dallas, Texas, March 1984.
4. Session Chairman: Postgraduate Course "Medical complications of pregnancy." Rush Medical College, Chicago, Illinois, November 1984.
5. Session Moderator: Young Investigator's Forum, American Heart Association, Los Angeles Affiliate. Los Angeles, California, May 1985.
6. Session Chairman: "Clinical Cardiology," 6th European Congress on Diseases of the Chest. Tel Aviv, Israel, June 1986.

7. Postgraduate Course Director: "Update in new and old cardiovascular drug therapy," University of Southern California, Los Angeles, California, April 1987.
8. Postgraduate Course Director: "Cardiovascular Drug Therapy II" - University of Southern California, Los Angeles, California, June, 1988.
9. Session Chairman: "Heart failure: drugs and devices," 61st Scientific Sessions of the American Heart Association, Washington, DC, November 1988.
10. Session Chairman: "Nitrate Tolerance," 62nd Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 1989.
11. Session Moderator: "Acute ischemic syndrome/pathophysiology and management," Fall Symposium, American Heart Association - Greater Los Angeles Affiliate, Los Angeles, California, September 1990.
12. Session Moderator: "When does therapy in heart failure prolong survival?" Fall Symposium, American Heart Association - Greater Los Angeles Affiliate, Los Angeles, California, September 1991.
13. Course Director: "Hypertension and heart failure: risk factors, prevention and treatment". University of Southern California, School of Medicine, Pasadena, California, May 1992.
14. Session Chairman: "Heart failure - flosequinan." 65th Scientific Sessions of the American Heart Association, New Orleans, LA. November 1992.
15. Session Chairman: "Heart failure - beta blockers." 65th Scientific Sessions of the American Heart Association, New Orleans, LA. November 1992.
16. Course Director: "Congestive Heart Failure: Management in the 90's." University of Southern California School of Medicine, Los Angeles, CA. January 1993.
17. Session Co-Chairman: "Pathophysiology." 2nd International Symposium on Heart Failure - Mechanisms and Management. Geneva, Switzerland, May 19, 1993.
18. Session Co-Chairman: "Hypertrophy, Hypertension." 2nd International Symposium on Heart Failure - Mechanisms and Management. Geneva, Switzerland, May 21, 1993.
19. Course Director: "Management of Heart Failure: 1993." University of Southern California School of Medicine, Pasadena, CA. June 1993.
20. Course Director: "From ischemia to heart failure: Management strategies," University of Southern California School of Medicine, Pasadena, CA. February 1994.
21. Session Co-Chairman: "How to manage end-stage heart failure," Meet the Experts Session, American College of Cardiology, 43rd Annual Scientific Session, Atlanta, GA. March 1994.
22. Session Co-Chairman: "Cardiovascular Clinical Pharmacology," American College of Cardiology, 43rd Annual Scientific Session. March 1994.
23. Symposium Chairman: "Nitrates in Heart Failure." 3rd International Symposium on Heart Failure - Mechanisms and Management. Geneva, Switzerland, May 22, 1995.

24. Session Co-Chairman: "Renal aspects, diuretics." 3rd International Symposium on Heart Failure - Mechanisms and Management. Geneva, Switzerland, May 22, 1995.
25. Session Co-Chairman: "Vascular biology." 3rd International Symposium on Heart Failure - Mechanisms and Management. Geneva, Switzerland, May 22, 1995.
26. Co-Chairman: "Nitrates." 6th International Symposium on Cardiovascular Pharmacotherapy. Sydney, Australia, February 29, 1996.
27. Session Co-Chairman: "Calcium antagonists and promoters." 4th International Symposium on Heart Failure - Mechanisms and Management. Jerusalem, Israel, May 27, 1996.
28. Co-Chairman: "Nitrates, vasodilators and newer drugs." 4th International Symposium on Heart Failure - Mechanisms and Management. Jerusalem, Israel, May 27, 1996.
29. Co-Chairman: "The treatment of congestive heart failure." 9th Annual Meeting of the Mediterranean Association of Cardiology and Cardiac Surgery. Tel Aviv, Israel, October 23, 1996.
30. Moderator - How to Session: "Pregnancy and heart disease" in the 69th Annual Scientific Sessions of the American Heart Association. New Orleans, Louisiana, November 11, 1996.
31. Program Director - Postgraduate Program: "Congestive heart failure 1997. Can care be improved at reduced cost?" University of Southern California. Pasadena, California, March 1, 1997.
32. Co-Chairman - Meet the Experts Session: "heart disease during pregnancy" in the 46th Annual Scientific Session, American College of Cardiology. Anaheim, California, March 16-19, 1997.
33. Chairman: Opening lecture in 5th world congress on heart failure mechanisms and management. Washington, D.C., May 11-14, 1997.
34. Co-Chairman: "Calcium channel blockers and promoters" in the 5th world congress on heart failure - mechanisms and management. Washington, D.C., May 11-14, 1997.
35. Co-Chairman - State of the art session: "Congestive heart failure and beta blockers" in the 7th International symposium on cardiovascular pharmacology. Jerusalem, Israel, June 1-5, 1997.
36. Moderator, Symposium on Treatment Strategies, First Annual Scientific Meeting, Heart Failure Society of America. Baltimore, Maryland. September 21-24, 1997.
37. Moderator Scientific Session on Heart Failure: pathophysiologic, hemodynamic, metabolic, and energetic factors. 70th Scientific Session, American Heart Association, Orlando, Florida, November 9-12, 1997.
38. Moderator-How-To-Session "How to manage the patients with adult congenital heart disease: an emerging population." 70th Scientific Session, American Heart Association, Orlando, Florida, November 9-12, 1997.

39. Program Director: Postgraduate Program. Congestive Heart Failure 1998: Update on prevention and treatment. @ University of Southern California, Pasadena, California, January 24, 1998.
40. Chairman, State of the Art Session - Management of heart failure in the CCU. International Meeting Intensive Cardiac Care. Jerusalem, Israel, June 30, 1998.
41. Program Director, Postgraduate program “Heart Failure 1999—an Update on Therapy,” University of Southern California, Los Angeles, California, January 1999.
42. Chairman: Plenary Session “Natriuretic Peptides, Endothelin: Role in Heart Failure, Washington, DC. In 1st International Congress on heart disease, new trends in research, diagnosis and treatment. May 16-19, 1999.
43. Chairman: Plenary Session “Natriuretic Peptides, Endothelin: Role in Heart Failure,” Washington, DC. May 19, 1999.
44. Moderator, Session on adverse and differential effects of heart failure therapy. 72nd Scientific Session, American Heart Association. Atlanta, Georgia, November 1999.
45. Program Director, Postgraduate program “Heart Failure 2000—an Update on Therapy.” University of Southern California, Los Angeles, California, January 29, 2000.
46. Chairman, Scientific Executive Committee and Chairman, Section on Clinical Trials. 7th World Congress on Heart Failure - Mechanisms and Management. Vancouver, B.C. Canada, July 9-12, 2000.
47. Chairperson, Opening Ceremony. 7th World Congress on Heart Failure - Mechanisms and Management. Vancouver, B.C., Canada, July 9-12, 2000.
48. Chairperson, Plenary Session "Cardiomyopathies: Hypertrophic and Dilated." 7th World Congress on Heart Failure - Mechanisms and Management. Vancouver, B.C. Canada, July 9-12, 2000.
49. Program Director, Postgraduate program “Heart Failure 2001—an Update on Therapy.” University of Southern California. Pasadena, California, January 27, 2001.
50. Moderator, Luncheon Panel on “Heart Failure: New Treatments.” 69th Annual Fall Symposium, American Heart Association, September 15, 2001.
51. Moderator, “Unconventional approaches – tomorrow’s headlines?” 18th Annual Santa Fe Colloquium on Cardiovascular Therapy of the American College of Cardiology, Santa Fe, New Mexico, October 5, 2001.
52. Program Director, postgraduate program “Heart Failure 2002 – An Update on Therapy.” University of Southern California. Pasadena, California, January 26, 2002.
53. Chair, “Natriuretic peptides in management.” Heart Failure Down Under, World Congress of Cardiology Satellite Meeting. Auckland, New Zealand, May 11-12, 2002.
54. Chair, “New treatment for decompensated heart failure – results of clinical trials and their clinical implications.” 3rd International Meeting – Intensive Cardiac Care. Jerusalem, Israel, June 26, 2002.

55. Fall Symposium Chair, American Heart Association 70th Annual Fall Symposium “Cardiology 2002 – An Update on Diagnosis and Therapy.” Los Angeles, California, October 12, 2002.
56. Program Director, postgraduate program “Heart Failure 2003 – An Update on Therapy.” University of Southern California. Los Angeles, California, January 25, 2003
57. Program Director, postgraduate program “Heart Failure 2004 – An Update on Therapy.” University of Southern California. Los Angeles, California, January 31, 2004.
58. Program Director, postgraduate program “Heart Failure 2005 – An Update on Therapy.” University of Southern California. Los Angeles, California, January 29, 2005
59. Program Director, postgraduate program “Heart Failure 2006 – An Update on Therapy.” University of Southern California. Los Angeles, California, January 28, 2006
60. Program Director, postgraduate program “Heart Failure 2007 – An Update on Therapy.” University of Southern California. Los Angeles, California, January 20, 2007.
61. Course Co Director, “Management of Acute and Chronic Heart Failure – Update 2007 “. University of Wisconsin school of medicine and public health. Milwaukee, WI, October 27, 2007
62. Conference Co-Chairman “Pregnancy and Heart Disease “. Northside hospital. Atlanta, Georgia. January 11-12, 2008
63. Program Director, postgraduate program “Heart Failure 2008 – An Update on Therapy.” University of Southern California. Los Angeles, California, February 2, 2008.
64. Conference Co-Director, Management of Acute and Chronic Heart Failure Update 2008”. Milwaukee, WI October 25. 2008.
65. Conference Co-Chair, “The 2nd Annual Pregnancy and Heart Disease Conference”. Atlanta, Georgia, February 13-14, 2009
66. Program Director, postgraduate program “Heart Failure 2009 An Update on Therapy”. Los Angeles, California, February 28, 2009.
67. Conference Co-Director, Management of Acute and Chronic Heart Failure Update 2008”. Milwaukee, WI October 25. 2009.
68. Program Director, postgraduate program “Heart Failure 2010 An Update on Therapy”. Los Angeles, California, January 30, 2010.
69. Congress chairman “The first international congress on cardiac problems in pregnancy”, Valencia, Spain, February 26-28, 2010.
70. Co-director “Congestive heart failure 2010: Update in pathophysiology and management”. Milwaukee, WI, April 17, 2010
71. Program director; post graduate program “Heart Failure 2011-An Update on Therapy”. Los Angeles, California, January 2011.

72. Congress chairman “The 2nd international congress on cardiac problems in pregnancy”, Berlin, Germany May 17-20, 2012.
73. Congress chairman “Pan America Heart Failure congress”, Panama-City, Panama, October 18-21, 2012.
74. Program director, postgraduate program “Heart Failure 2013- An Update on Therapy”. Los Angeles, California, April 6, 2013.
75. Congress Chairman “The 3rd International Congress on Cardiac Problems in Pregnancy”, Venice, Italy, 20-23 February 2014.
76. Program director “Heart failure 2014-An update on therapy”. Los Angeles, California, April 2014.
77. Program director “Heart failure 2015-Am update on therapy”. Los Angeles, California, April 2015.
78. Congress chairman “The 4th international congress on cardiac problems in pregnancy”, Las Vegas, Nevada, United States, February 2016.
79. Program director “Heart Failure 2016-An update on therapy”. Los Angeles, California, April 2016.
80. Program director “Heart Failure 2017-An update on therapy” Los Angeles, California, April 2017.
81. Program director “Innovations in cardiovascular diagnosis and therapy”. Los Angeles California October 2017.
82. Congress Chairman “The 5th international congress on cardiac problems in pregnancy”, Bologna Italy, February 2018.
83. Program director “Heart failure 2018-An update on therapy”, Los Angeles, California April 2018.
84. Program director “Heart Failure 2019-An update on therapy”, Los Angeles, California, April 2019.
85. Program director “Cardio-Obstetrics” meeting, Chicago, Illinois, September 2019.
86. Program director “Heart Failure 2020-An update on therapy” a virtual meeting, August 2020.
87. Program director “Cardio-Obstetrics 2020” a virtual meeting, September 2020.
88. Congress chairman “The 6th international congress on cardiac problems in pregnancy”. A virtual symposium. February 11-14, 2021.
89. Program director “Heart Failure 2021-an update on therapy” A virtual symposium, March 11-12, 2021.
90. Program director “Cardio Obstetrics 2021”, October 2021.

91. Program director “Heart failure 2022-an update on therapy” a virtual symposium, March 2022.
92. Congress chairman: The 7th international congress on cardiac problems in pregnancy”, Porto, Portugal, September 2022.

MEDICAL SCHOOL THESIS

Elkayam U: Cardiac involvement in systemic lupus erythematosus: a clinical and echocardiographic study. Thesis Sackler Medical School, Tel-Aviv, Israel 1973.

ARTICLES

1. Goland S, George J, **Elkayam U**, Shimoni S, Fugenfirov I, Vaisbuch E, Arad M, Freimark D, Simchen M, Kuperstein R. Contemporary outcome of subsequent pregnancies in patients with previous peripartum cardiomyopathy. *ESC Heart Fail*, 2022 Dec;9(6):4262-4270
2. Pizula J, Devera J, Ng TMH, Yeung SL, Thangathurai J, Herrick N, Chatfield AJ, Mehra A, **Elkayam U**. Outcome of Pregnancy in Women With D-Transposition of the Great Arteries: A Systematic Review. *J Am Heart Assoc*. 2022 Dec 6;11(23):e026862.
3. Ramlakhan KP, Malhame I, Marelli A, Rutz T, Goland S, Franx A, Sliwa K, **Elkayam U**, Johnson MR, Hall R, Cornette J, Roos-Hesselink JW. Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry. *European Heart Journal*. 2022 Jun 21.
4. Triska J, Tamargo J, Bozkurt B, **Elkayam U**, Taylor A, Birnbaum Y. An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. [Review]. *Cardiovascular Drugs & Therapy*. 2022 Mar 31
5. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Pacheco LD, Saade G, Shrivastava V, Shree R, **Elkayam U**, Publications Committee. Society for Maternal-Fetal Medicine Consult Series #61: Anticoagulation in pregnant patients with cardiac disease. *American Journal of Obstetrics & Gynecology*. 227(2):B28-B43, 2022 08.
6. Tamirisa KP, **Elkayam U**, Briller JE, Mason PK, Pillarisetti J, Merchant FM, Patel H, Lakkireddy DR, Russo AM, Volgman AS, Vaseghi M . Arrhythmias in pregnancy. *JACC. Clinical Electrophysiology*. 8(1):120-135, 2022 01.
7. DeFilippis FM, Beale A, Martin T, Cogswell R, Agarwal A, **Elkayam U**, Lam CSP, Hsieh E. Heart Failure Subtypes and Cardiomyopathies in Women. *Circulation Research*. 130(4):436-454, 2022 02 18

8. Kamala P, Tamirisa KP, **Elkayam U**, Biller JE, Mason PK, Pillarisetti J, Merchant FM, Patel H, Lakkireddy DR, Russo AM, Volgman AS, Marmar V. Arrhythmias in pregnancy. *JACC electrophysiol* 2021
9. Shotan A, Roos Hesselink J, Goland S, Yekel Y, **Elkayam U**. Cardiomyopathy, and pregnancy considerations for women with severe reduced left ventricular dysfunction. *Can J Cardiol* 2021 September 29
10. Reddy P, **Elkayam U**. The Hidden Cost of Meth: Appraising the Socioeconomic Burden of Methamphetamine-Associated Cardiomyopathy. *Circ Cardiovasc Qual Outcomes*. 2021;14:e008214.
11. Reddy PK, Chau E, Patel SV, Yang K, Ng TM, **Elkayam U**. Characteristics of Methamphetamine-associated Cardiomyopathy, and the Impact of Methamphetamine Use on Cardiac Dysfunction. *Am J Cardiol*. 2021; 4: S0002-9149(21)00529-4.
12. Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, DePalma S, Haghighi A, Seidman JG, Seidman CE, Jacoby D, Macones G, Judge DP, Rana S, Margulies KB, Cappola TP, Alharethi R, Damp J, Hsich E, **Elkayam U**, Sheppard R, Alexis JD, Boehmer J, Kamiya C, Gustafsson F, Damm P, Ersbøll AS, Goland S, Hilfiker-Kleiner D, McNamara DM; IMAC-2 and IPAC Investigators, Arany Z.. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy Circulation. 2021 May 11;143(19):1852-1862
13. Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D, Zile MR, **Elkayam U**, Fong MW, Grazette LP. Acute pulmonary pressure changes after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. *ESC Heart Fail* 2021 Apr;8(2):1706-1710.
14. Polsinelli VB, Hanley-Yanez K, Charles F. McTiernan CF, Modi K, Haythe J, Skopicki H, **Elkayam U**, Cooper LT, Fett DT, McNamara DM, for the IPAC investigators. Cathepsin-D and Outcomes in Peripartum Cardiomyopathy: Results from IPAC. submitted
15. **Elkayam U**, Shmueli H. Pregnancy in women with rheumatic valve disease: how to improve the outcome? *Heart* 2020 July.
16. Rahul Goli¹, Jian Li¹, Jeff Brandimarto¹, Quentin McAfee¹, Steven DePalma², Daniel Jacoby³, George Macones⁴, Daniel Judge⁵, Sarosh Rana⁶, Kenneth Margulies¹, Thomas P. Cappola¹, Rami Alharethi⁷, Julie Damp⁸, Eileen Hsich⁹, Uri **Elkayam**¹⁰, Richard Sheppard¹¹, Jeffrey Alexis¹², John Boehmer¹³, Chizuko Kamiya¹⁴, Anne Ersbøll¹⁵, Sorel Goland¹⁶, Denise Hilfiker-Kleiner¹⁷, Dennis M. McNamara¹⁸, the IMAC-2 and IPAC investigators¹⁹, and Zolt Arany¹ Genetic and phenotypic landscape of peripartum cardiomyopathy. submitted
17. Polsinelli VB, MD¹, Hanley-Yanez K, BS¹, McTiernan CF, PhD¹, Modi K, MD², Haythe J, MD³, Skopicki H, MD, PhD⁴, **Elkayam U**, MD⁵, Cooper LT, MD⁶, Fett JD, MD^{1,7}, McNamara DM, MD, MS¹ for the IPAC investigators, Cathepsin-D and Outcomes in Peripartum Cardiomyopathy: Results from IPAC submitted

18. Reddy PKV, Ng TMH, Oh EE, Moady G, **Elkayam U**. Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review. *J Am Heart Assoc* 2020 un 2;9(11):e016704
19. Ng TMH, Grazette LP, Fong MW, Yoon AJ, Lou M, Kuo M, Upadhyay RY, Han EE, Mehra A, **Elkayam U**. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF). *ESC Heart Fail* 2020; doi: 10.1002/ehf2.12783
20. Davis M, Arany Z, McNamara DM, Goland S, **Elkayam U**. Peripartum cardiomyopathy: JACC state of the art review. 2020; 75:207-221.
21. **Elkayam U**, Schäfer A, Chieffo A, Lansky A, Hall S, Arany Z, Grines C. Use of Impella heart pump for management of women with peripartum cardiogenic shock. *Clin Cardiol*. *Clin Cardiol* 2019; 42:974-981
22. Honigberg MC, **Elkayam U**, Rajagopalan N, Modi K, Briller JE, Drazner MH, Wells GL, McNamara DM, Givertz MM; IPAC Investigators. Electrocardiographic findings in peripartum cardiomyopathy. *Clin Cardiol* 2019; 42:524-529.
23. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, **Elkayam U**, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). *Eur Heart J* 2019, March 25.
24. Koczo A, Marino A, Jeyabalan A, **Elkayam U**, Cooper LT, Fett J, Briller J, Hsich E, Blauwet B, McTiernan c, Morel1PA, Hanley-Yanez K, McNamara DM for the IPAC Investigators: Breastfeeding, Cellular Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy (PPCM). *JACC BTS* 2019; 4:291-300.
25. Damp JA, arany Z, Fett D, Blauwet L, **Elkayam U**. Imbalanced angiogenesis in peripartum cardiomyopathy (PPCM). *Circulation J* 2018; 82:2689.
26. Peterson EJ, Ng TMH, Patel KA, Lou M, **Elkayam U**. Association of admission vs. nadir serum albumin concentration with short-term treatment outcomes in patients with acute heart failure. *J Int Med Res* 2018; 46:3665-3674.
27. **Elkayam U**. How to Predict Pregnancy Risk in an Individual Woman with Heart Disease. *J Am Coll Cardiol* 2018; 71:2431-243
28. Goland S, **Elkayam U**. Peripartum cardiomyopathy: approach to management. *Curr Opin Cardiol* 2018; 33:347-53.
29. **ElkayamU**, Havakuk O. Pregnancy associated coronary dissection: A therapeutic dilemma. *J Am Coll Cardiol* 2018; 71:569-470
30. **Elkayam U**. Can I get pregnant again? *Eur J Heart Failure* 2017; 19:1729-31.

31. Goland S, **Elkayam U**. Pregnancy and Marfan syndrome. *Ann Cardiovasc Surg* 2017; 6:642-653
32. **Elkayam U**. Peripartum cardiomyopathy for the clinician: the known and the unknown. *Eur J Heart Failure* 2017;19: online.
33. Havakuk O, King KS, Grazette L, Yoon AJ, Fong M, Bregman N, **Elkayam U**, Kloner RA. Heart failure induced brain injury. *J Am Coll Cardiol* 2017; 69:1609-1616
34. **Elkayam U**. Anticoagulation therapy for pregnant women with mechanical prosthetic heart valves, how to improve safety? *J Am Coll Cardiol* 2017; 69:2692-2695
35. Havakuk O, Goland S, Mehra A, **Elkayam U**. Pregnancy and the risk of spontaneous coronary dissection. An analysis of 120 contemporary cases. *Circulation CV Interven* 2017; 10: e004941.
36. Schelbert EB, **Elkayam U**, Cooper L, Givertz MM, Alexis J, Briller J, Felker MG, Chaparro SV, Kealey A, Pisarcik J, Fett J, McNamara DM. Myocardial damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. *J Am Heart Assoc* 2017;6 e005472.210.
37. Havakuk O, King KS, Grazette L, Yoon AJ, Fong M, Bregman N, **Elkayam U**, Kloner R. Heart failure and brain injury. *J Am Heart Assoc* 2017; 69:1609-16
38. Havakuk O, **Elkayam U**. Angiotensin receptor –Neprilysin inhibition: New therapeutic concepts in the management of chronic heart failure, development, clinical implications and future perspectives. *J CV Pharmacol Ther* 2017
39. Narayanan M, **Elkayam U**, Naqvi TZ. Echocardiography in pregnancy: part 2. *Current Cardiol Reports* 2016;18:90.
40. Liu S, **Elkayam U**, Naqvi TZ. Echocardiography in pregnancy: part 1. *Current Cardiol Reports* 2016;18: 92
41. **Elkayam U**, Goland S, Pieper PG, Silversides CK. High risk cardiac disease in pregnancy part II. *JACC* 2016; 68:502-16
42. **Elkayam U**, Goland S, Pieper PG, Silversides CK. High risk cardiac disease in pregnancy part I. *JACC* 2016; 68:396-410
43. Sheppard R; Hsich E, Damp J, **Elkayam U**, Kealey A; Ramani G, Zucker M, Alexis a, Horne B, Hanley-Yanez K, Pisarcik J, BSN; Halder I, Fett J, McNamara D for the IPAC Investigators. GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study. *Circulation Heart Failure* 2016; 9: e002683
44. **Elkayam U**, Havakuk O. The Search for a Crystal Ball to Predict Early Recovery from Peripartum Cardiomyopathy? *JACC Heart Fail* 2016; 4(5): 389-91.
45. Arany Z, **Elkayam U**. Peripartum cardiomyopathy. *Circulation* 2016 5;133(14):1397-409

46. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, **Elkayam U**, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J 3rd, McNamara DM, Seidman CE, Seidman JG, Arany Z; IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. *N Engl J Med.* 2016; 374(3):233-41
47. Ng TMH, Goland S. **Elkayam U**. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence. *Cardiology in Review* 2015; 24:194-204.
48. McNamara DM, **Elkayam U**, Alharethi R, Damp J, Hsich R, Ewald G, Moki K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J, Wu WC, Lin X, Halder I, Pisarcik J, Cooper LT, Fett J for the IPAC investigators. Clinical outcome for peripartum cardiomyopathy in north America; Results of the investigation of pregnancy associated cardiomyopathy (IPAC) study. *J Am Coll Cardiol.* 2015; 66:905-14.
49. Goland S, **Elkayam U**. On mice and (wo)men. *Trends in Cardiovasc Med* March 2015; 25:505-7
50. **Elkayam U**. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. *J Am Coll Cardiol* 2014; 64:1629-36.
51. Ruys TPE, Maggioni A, Johnson MR, Sliwa K, Tavazzi L, Schwezmann M, Nihoyannopoulos P, Kozelj M Marelli A, **Elkayam U**, Hall R, Roos-Hesslink JW. Cardiac medications during pregnancy, data from the ROPAC . *Int J Cardiol* 2014; 177:124-128.
52. Ferdinand KC, **Elkayam U**, Mancini D, Ofili E, Pina I, Anand I, Feldman AM, McNamara D, Leggett C. Heart Failure in African America: the 2013 American College of cardiology foundation/American association (ACCF/AMA) guidelines, isosorbide dinitrate, hydralazine and A-HeFT- 9 years on. *Am J Cardiol* 2014
53. Ng TMH, Cao DX, Patel KA, Wong YM, Prasad M, Lou M, **Elkayam U**. Association of hyponatremia to diuretic response and incidence of increased serum creatinine levels in hospitalized patients with acute heart failure. *Cardiology* 2014; 128:333-342.
54. **Elkayam U**, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, Roth A. Pregnancy-Associated Acute Myocardial Infarction: A Review of Contemporary Experience in 150 Cases Between 2006 and 2011. *Circulation* 2014; 129:1695-1702.
55. Sliwa K, Hilfiker-Kleiner D, Mobazaa A, Petrie MC, Maggioni AP, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, Van Veldhuisen DT, Roos-Hesslink JW, Seferovic PM, **Elkayam U**, Van Spaendonk-Zwarts K, Bachelier-Walenta K, Moufhet F, Kraigher-Krainer E, Hall R, Ponikowski P, McMurray JJV, Pieske B. EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. *Eur Heart J* Feb 2014

56. Goland G, Schwartzberg S, Fan J, Kozak, Nudrat N, Khatri N, **Elkayam U**. Monitoring of Anti-Xa in Pregnant Patients with Mechanical Prosthetic Valves Receiving Low-Molecular-Weight Heparin: Peak or Trough Levels. *J Cardiovascular Pharmacol Therap.* March 6, 2014
57. Packer M, Carson P, **Elkayam U**, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL and PRAISE-2 Study Group
58. Goland S, Zilberman L, **Elkayam U**. Clinical Considerations on Anticoagulation Management in Cardiovascular Diseases During Pregnancy. *Drug Development Research*, Dec 2013; 74(8).
59. Ng TM, Konopka E, Hyderi AF, Hshieh S, Tsuji Y, Kim BJ, Han SY, Phan DH, Jeng AI, Lou M, **Elkayam U**. Comparison of bumetanide- and metolazone diuretic regimens to furosemide in acute heart failure. *Journal of Cardiovascular Pharmacology & Therapeutics.* 18(4):345-53, 2013
60. Schwartzberg S, Perlman S, Levy R, **Elkayam U**, Goland, S. Mechanical heart valve thrombosis in pregnancy. *Journal of Heart Valve Disease.* 22(4): 603-6, 2013.
61. Gleicher N, **Elkayam U**. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. *Autoimmunity Reviews.* 12(11): 1039-45, 2013
62. Colletti PM, Lee KH, **Elkayam U**. Cardiovascular imaging of the pregnant patient. *Am J Roentgenology.* 210(3); 200:515-21
63. Quzounian JG, **Elkayam U**. Physiologic changes during normal pregnancy and delivery. *Clinical cardiology* 2012; 30:317-330
64. Ng TMH, Hshieh S, Shenche MS, Chan CY, **Elkayam U**. clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. *J Cardiovasc Pharmacol Therap.* 2012; 17:373-81
65. Ng TMH, Ackerbauer KA, Hyderi AF, Hshieh A, **Elkayam U**. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. *J Cardiovascular Pharmacol Therap.* 2012; 17: 79-85
66. Naqvi TZ, **Elkayam U**. Serial Echocardiographic Assessment of the Human Heart in Normal Pregnancy. *Circulation. Cardiovascular imaging.* 5(3): 283-5, 2012
67. **Elkayam U**, Goland S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. *J Am Coll Cardiol.* 59(12): 1116-8, 2012
68. European Society of Gynecology. Association for European Paediatric Cardiology. German Society for Gender Medicine. Authors/Task Force Members. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos

P. Pieper PG. Presbitero P. Roos-Hesselink JW. Schaufelberger M. Seeland U. Torracca L. ESC Committee for Practice Guidelines. Bax J. Auricchio A. Baumgartner H. Ceconi C. Dean V. Deaton C. Fagard R. Funck-Brentano C. Hasdai D. Hoes A. Knuuti J. Kolh P. McDonagh T. Moulin C. Poldermans D. Popescu BA. Reiner Z. Sechtem U. Sirnes PA. Torbicki A. Vahanian A. Windecker S. Document Reviewers. Baumgartner H. Deaton C. Aguiar C. Al-Attar N. Garcia AA. Antoniou A. Coman I. **Elkayam U**. Gomez-Sanchez MA. Gotcheva N. Hilfiker-Kleiner D. Kiss RG. Kitsiou A. Konings KT. Lip GY. Manolis A. Mebaaza A. Mintale I. Morice MC. Mulder BJ. Pasquet A. Price S. Priori SG. Salvador MJ. Shotan A. Silversides CK. Skouby SO. Stein JI. Tornos P. Vejlstrup N. Walker F. Warnes C. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J*. 32(24): 3147-97, 2011

69. **Elkayam U**. Clinical characteristics of peripartum cardiomyopathy in the US: Diagnosis, prognosis and management. *J Am Coll Card* 2011; 58: 659 - 670.
70. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, Khatri N, **Elkayam U**. Evaluation of the Clinical Relevance of Baseline Left Ventricular Ejection Fraction as a Predictor of Recovery or Persistence of Severe Dysfunction in Women in the United States with Peripartum Cardiomyopathy. *J Cardiac Fail* 2011; 17:426-430.
71. Goland S, Tsai F, Habib M, Janmohamed M, Goodwin TM, **Elkayam U**. Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension. *Cardiology*. 2010; 115: 205-8.
72. **Elkayam U**, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. *Circulation*. 2010; 121: 1463-4.
73. Sarma RJ, Chana A, **Elkayam U**. Left ventricular non compaction. *Progress in Cardiovasc Dis*. 2010; 52: 264-73.
74. Falk RH, **Elkayam U**. Cardiomyopathy the importance of recognizing the uncommon diagnosis. *Progress in Cardiovasc Dis*. 2010; 52: 262-3.
75. Ng TM, Tsai F, Khatri N, Barakat MN, **Elkayam U**. Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention. *Circulation Heart Fail*. 2010; 3: 165-73.
76. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebaaza A, Piesk B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, Van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, **Elkayam U**, Pankuweit S, Papp Z, Mouquet F, McMurray JJ. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *Eur J Heart Fail*. 2010; 12:767-78.
77. Giles TD, **Elkayam U**, Bhattacharya M, Perez A, Miller AB. Comparison of pioglitazone vs. Glyburide in early heart failure: insights from a randomized controlled study of

patients with type 2 diabetes and mild cardiac disease. *Congestive Heart Fail.* 2010; 16:111-7.

78. Cordasco KM, Asch SM, Bell DS, Guterman JJ, Gross-Schulman S, Ramer L, **Elkayam U**, Franco I, Leatherwood CL, Mangione CM. A low-literacy medication education tool for safety-net hospital patients. *Am J of Prevent Med.* 2009; 37: S209-16.
79. Goland S, Barakat M, Khatri N, **Elkayam U**. Pregnancy in Marfan syndrome: maternal and fetal risk and recommendations for patient assessment and management. *Cardiol in Rev.* 17:253-62, 2009.
80. Palardy M, Stevenson LW, Tasissa G, Hamilton MA, Bourge RC, Disalvo TG, **Elkayam U**, Hill JA, Reimold SC. ESCAPE Investigators. Reduction in mitral regurgitation during therapy guided by measured filling pressures in the ESCAPE trial. *Circulation: Heart Fail.* 2:181-8, 2009 May.
81. Metra M, Eichhorn E, Abraham W.T, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, **Elkayam U**, Gerber M, Komajda M, Liu P, Mareev V, Perrone Sergio P.V, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow M.R, Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. *Eur Heart J.* 2009; 30:3015-26
82. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LSC, Illum S, Hatamizadeh P, **Elkayam U**, Clinical Profile and Predictors of Complications in Peripartum Cardiomyopathy. *J Card Fail.* 2009; 15:645-50.
83. **Elkayam U**, Beta-Blocker in the Treatment of Aortic Regurgitation, A New Opportunity? *J Am Coll Cardiol.* 2009; 54: 458-9.
84. Hameed AB, Chan K, Ghamsary M, **Elkayam U**, Longitudinal Changes in the B-Type Natriuretic Peptide Levels in Normal Pregnancy and Postpartum. *Clin Cardiol.* 2009, 32: E60-2.
85. **Elkayam U**, Janmohamed M, Hatamizadeh P, Heywood JT, Wei LJ, Mills RM. Impact of acute serum creatinine elevation in patients treated with nesiritide. *Clin Cardiol.* 2009; 32:215-19.
86. Goland S, **Elkayam U**. Cardiovascular problems in pregnant women with Marfan syndrome. *Circulation* 2009; 119:619-23.
87. Gleicher N, **Elkayam U**. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? *Autoimmune Rev* 2009; 8:384 -7.
88. Goldsmith SR, **Elkayam U**, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2 – receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. *J Card Fail* 2008; 14:641-7.

89. Giles TD, Miller AB, **Elkayam U**, Bhattacharya M, Prez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systabio dysfunction. *J Card Fail* 2008; 14:445-52.
90. **Elkayam U**; Ng TMH; Hatamizadeh P; Janmohamed M; Mehra A, Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. *Circulation*. 2008; 117:200-205,
91. **Elkayam U**. Janmohamed M. Habib M. Hatamizadeh P. Vasodilators in the management of acute heart failure. *Critical Care Med*. 2008; 36(1 Suppl): S95-105.
92. Roth A. **Elkayam U**. Acute myocardial infarction associated with pregnancy. *J Am Coll of Cardiol*.2008; 52:171-80.
93. Puri P. Mehra A. **Elkayam U**. Cheyne-Stokes respiration and cardiac hemodynamics in heart failure. *Catheterization & Cardiovascular Interventions*. 2008; 72:581-5.
94. **Elkayam U**. Tasissa G. Binanay C. Stevenson LW. Gheorghide M. Warnica JW. Young JB. Rayburn BK. Rogers JG. DeMarco T. Leier CV. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. [Journal Article. Research Support, N.I.H., Extramural] *Am Heart J*.2007; 153:98-104.
95. **Elkayam U**. Hatamizadeh P. Janmohamed M. The challenge of correcting volume overload in hospitalized patients with decompensated heart failure. *J Am Coll Cardiol*. 2007; 49:684-6.
96. Hameed AB. Goodwin TM. **Elkayam U**. Effect of pulmonary stenosis on pregnancy outcomes--a case-control study. *Am Heart J*. 2007; 154:852-4.
97. Payvar S, Orlandi C, Stough W, **Elkayam U**, Ouyang J, Casscells W and Gheorghide M,: Comparison of 60-Day Mortality in Hospitalized Heart Failure Patients With Versus Without Hypothermia *Am J Cardiol*. 2006; 98:1485–88.
98. Sliwa K, Fett J, **Elkayam U**, Current understanding of the epidemiology, aetiology, clinical profile, and management of PPCM, *Lancet*. 2006; 368:687–93.
99. **Elkayam U**, Bitar F: Effects of Nitrates and Hydralazine in Heart Failure: Clinical Evidence Before African American Heart Failure Trial. *Am J Cardiol*. 2005; 96:37i-43i.
100. Hameed A, Akhter MW, Bitar F, Khan SA, Sarma R, Goodwin TM, **Elkayam U**: Left atrial thrombosis in pregnant women with mitral stenosis and sinus rhythm. *Am J Obstet Gynecology*. 2005; 193:501-4.
101. Seshadri N, Goldhaber SZ, **Elkayam U**, Grimm RA, Groce JB, Heit JA, Spinler SA, Turpie AGG, Bosker G, Klein AL: The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: An evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. *Am Heart J*. 2005; 150:27-34.

102. **Elkayam U**, Bitar F: Valvular Heart Disease and Pregnancy: Part I: Native Valves. *J Am Coll Cardiol.* 2005; 46:223-30.
103. **Elkayam U**, Bitar F: Valvular Heart Disease and Pregnancy: Part II: Prosthetic Valves. *J Am Coll Cardiol.* 2005; 46:403-10.
104. Gullestad L, Wikstrand J, Deedwania P, Hjalmarson Å, Egstrup K, **Elkayam U**, Gottlieb S, Rashkow A, Wedel H, Bermann G, Kjekshus J for the MERIT-HF Study Group: What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). *J Am Coll Cardiol.* 2005; 45:252-9.
105. **Elkayam U**, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A: Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation. *Circulation.* 2005; 111:2050-5.
106. Konstam MA, Francis GS, Greenberg B, Strobeck, JE, Packer M, Adams KF, Bennett SJ, Bristow MR, Cohn JN, Colucci, WS, **Elkayam U**, Krumholz HK, Liu PP, Mann DL, Piña IL, Sabbah HN: Heart failure training: A call for an integrative, patient-focused approach to an emerging cardiology subspecialty. *J Cardiac Failure* 2004; 10:366-367.
107. Bitar F, Akhter MW, Khan S, Singh H, **Elkayam U**: A Survey of the Use of Organic Nitrates for the Treatment of Chronic Heart Failure in the United States. *Am J Cardiol.* 2004; 94:1465–8.,
108. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger A, **Elkayam U**: Effect of Elevated Admission Serum Creatinine and its Worsening on Outcome in Hospitalized Patients with Decompensated Heart Failure, *Am J Cardiol.* 2004; 94:957-60.
109. **Elkayam U**, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshaini M: Intravenous Nitroglycerin in the Treatment of Decompensated Heart Failure: Potential Benefits and Limitations. *J Cardiovasc Pharmacol Therapeut.* 2004; 9:227-41.
110. **Elkayam U**, Singh H, Irani A, Akhter MW: Anticoagulation in Pregnant Women with Prosthetic Heart Valves. *J Cardiovasc Pharmacol Therapeut.* 2004; 9:107-15.
111. Gheorghiad M, Gattis, WA, O'Connor CM, **Elkayam U**, Adams Jr, KA, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C: Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure A Randomized Controlled Trial. *JAMA.* 2004; 291:1963-71.
112. Qasqas SA, McPherson C, Frishman WH, **Elkayam U**: Cardiovascular Pharmacotherapeutic Considerations During Pregnancy and Lactation. *Cardiology in Review.* 2004; 12:240-61.
113. **Elkayam U**, Akhter MMW, Singh H, Khan S, Usman A: Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. *Am J Cardiol.* 2004; 93:237-40.

114. Canetti M, Akhter MW, Lerman A, Karaalp IS, Zell JA, Singh H, Mehra A, **Elkayam U**: Evaluation of myocardial blood flow reserve in patients with chronic heart failure due to idiopathic dilated cardiomyopathy. *Am J Cardiol.* 2003; 92:1246-9.
115. Torre-Amione G, Young JB, Colucci WS, Lewis Bs, Pratt C, Cotter G, Stangl K, **Elkayam U**, Teerlink JR, Frey A, Rainisio M, Kobrin I: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure *Clinical Trial. Journal Article, Multicenter Study, Randomized Controlled Trial.* *J Am Coll Cardiol.* 2003,42:140-7.
116. Gheorghiadu M, Gattis WA, Barbagelata A, Adams KF Jr, **Elkayam U**, Orlandi C, O'Connor CM: Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. *Am Heart J.* 2003; 145:S51-4.
117. **Elkayam U**, Akhter MW, Tummala P, Khan S, Singh H: Nesiritide: A new drug for the treatment of decompensated heart failure. *J Cardiovasc Pharmacol Therapeut.* 2002; 7:181-94.
118. **Elkayam U**, Khan S, Mehboob A, Ahsan N. Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy. *J Card Failure.* 2002; 8:15-20.
119. **Elkayam U**. Pregnant again after peripartum cardiomyopathy: to be or not to be? *Eur Heart J.* 2002; 23:753-6.
120. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng MI, **Elkayam U**: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. *Am Heart J.* 2002; 144:1102-8.
121. Publication Committee for the VMAC Investigators: Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure: A Randomized Controlled Trial. *JAMA.* 2002; 287:1531- 40.
122. Silver MA, Horton DP, Ghali JK, **Elkayam U**: Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. *J Am Coll Cardiol.* 2002; 39:798-803.
123. **Elkayam U**, Khan S, Mehboob A, Ahsan N: Impaired Endothelium - Mediated Vasodilation in Heart Failure-Clinical Evidence and the Potential for therapy. *J Cardiac Failure.* 2002; 8:15-20.
124. Hameed A. Karaalp IS. Tummala PP. Wani OR. Canetti M. Akhter MW. Goodwin I. Zapadinsky N. **Elkayam U**. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. *J Am Coll Cardiol.* 2001; 37,893-9.

125. **Elkayam U**, Prakash M, Subbiah S, Mehdi S, Nikitina A, Akhter W. Endothelial function in patients with chronic heart failure. *J Cardiac Failure*. 2001; 38 Suppl 2: S47-S48.
126. Loh E, **Elkayam U**, Cody R, Bristow M, Jaski B, Colucci WS. A Randomized Multicenter Study Comparing the Efficacy and Safety of Intravenous Milrinone and Intravenous Nitroglycerin in Patients with Advanced Heart Failure. *J Cardiac Failure* 2001; 7:114-21.
127. Burger AJ, **Elkayam U**, Neibaur MT, Haught H, Ghali J, Horton DP, Aronson D: Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. *Am J Cardiol*. 2001; 88:35-9.
128. **Elkayam U**, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, Hameed A, Gviatzda I, Shotan A: Maternal and fetal outcomes of subsequent pregnancies in women with Peripartum Cardiomyopathy *N Engl J Med*. 2001; 344:1567-71.
129. Hameed AB, Karaalp IS, Tummala PP, Wani OR, Canetti M, Akhter MW, Goodwin M, Zapadinsky N, **Elkayam U**: The Effect of Valvular Heart Disease on Maternal and Fetal Outcome of Pregnancy. *J Am Coll Cardiol*. 2001; 37:893-9.
130. Colucci WS, **Elkayam U**, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH: Intravenous nesiritide, A natriuretic peptide, in the treatment of decompensated congestive heart failure. *N Engl J Med*. 2000; 343:246-53.
131. Hameed AB, Tummala PP, Goodwin TM, Nuno I, Wani OR, Karaalp IS, **Elkayam U**: Unstable angina during pregnancy in two patients with premature coronary atherosclerosis and aortic stenosis in association with familial Hypercholesterolemia. *Am J Obstet Gynecol*. 2000; 182:1152-5.
132. Levine B, Bernink PJ, Caspi A, **Elkayam U**, Geltman EM, Greenberg B, Mc Kenna, WJ, Ghali JK, Giles TD, Marmor A, Reisin LH, Ammon S, Lindberg E: Effect of Mibefradil, A T-type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure—the MACH-1 Study. *Circulation*. 2000; 101:758-64.
133. O'Connor CM, Gattis WA, Gheorghiane M, Granger CB, Gilbert J, McKenney JM, Messineo FC, Burnett JC, Katz SD, **Elkayam U**, Kasper EK, Goldstein S, Cody RJ, Massie BM for the U.S. Ecadotril Investigators: A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. Ecadotril Pilot Safety Study. *Am Heart J*. 1999; 138:1140-8.
134. Goodwin TM, Gherman RB, Hameed A, **Elkayam U**: Favorable response of Eisenmenger syndrome to inhaled nitric oxide during pregnancy. *Am J Obstet Gynecol*. 1999; 180:64-7.
135. **Elkayam U**: Pregnancy Through a Prosthetic Heart Valve. *J Am Coll Cardiol* for publications. 1999; 33:1642-8.
136. **Elkayam U**, Karaalp IS, Wani OR, Tummala P, Akhter MW: The Role of Organic Nitrates in the Treatment of Heart Failure. *Prog cardiovasc Dis*. 1999; 41:255-64.

137. **Elkayam U**, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, Wani OR, Karaalp, IS: A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Organic Nitrates in Patients with Chronic Heart Failure Treated with Angiotensin Converting Enzyme Inhibition. *Circulation*. 1999; 99:2652-57.
138. **Elkayam U**: Calcium channel blockers in heart failure. *Cardiology*. 1998;(Suppl 1): 38-46.
139. Hurst AK, Shotan A, Hoffman K, Johnson J, Goodwin TM, Koda R, **Elkayam U**: Pharmacokinetic and pharmacodynamic evaluation of atenolol during and after pregnancy. *Pharmacotherapy*. 1998; 18:840-6.
140. **Elkayam U**, Canetti M, Wani OR, Karaalp IS, Tummala PP: Hydralazine-induced prevention of nitrate tolerance: Experimental and clinical evidence and potential mechanisms. *Am J Cardiol*. 1998; 81:44A-8A.
141. **Elkayam U**, Mehra A, Cohen G, Tummala PP, Karaalp IS, Wani OR, Canetti M: Renal circulatory effects of adenosine in patients with chronic heart failure. *J Am Coll Cardiol*. 1998; 32:211-5.
142. Lang RM, **Elkayam U**, Yellen LG, Krauss D, McKelvie RS, Vaughan D, Ney DE, Makris L, Chang PI: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. *J Am Coll Cardiol*. 1997; 30:983-91.
143. Shotan A, Ostrzega E, Mehra A, Johnson J, **Elkayam U**: Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness and syncope. *Am J Cardiol*. 1997; 79:1061-4.
144. Roth A, **Elkayam U**: Acute myocardial infarction in pregnancy. *Am Int Med*. 1996; 125:751-62.
145. **Elkayam U**: Prevention of nitrate tolerance with concomitant administration of hydralazine. *Can Heart J*. 1996; 12:17C-21C.
146. **Elkayam U**, Cohen G, Gogia H, Mehra A, Johnson JV, Chandraratna, PAN: Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. *J Am Coll Cardiol*. 1996; 28:176-82.
147. **Elkayam U**: Anticoagulation in pregnant women with prosthetic heart valves: A double jeopardy. *J Am Coll Cardiol*. 1996; 27:1704- 6.
148. **Elkayam U**: Nitrates in the treatment of congestive heart failure. *Am J Cardiol*. 1996; 77:41C-51C.
149. Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, **Elkayam U**: Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. *J Am Coll Cardiol*. 1995; 26:1575-80.
150. Mehra A, Shotan A, Ostrzega E, Johnson J, **Elkayam U**: Escalating nitrate dose as a strategy for counteracting early attenuation of effect due to nitrate tolerance in patients with heart failure. *Am Heart J*. 1995; 130:798-805.

151. **Elkayam U**, Ostrzega E, Shotan A, Mehra A: Cardiovascular problems in pregnant women with the Marfan syndrome. *Ann Int Med.* 1995; 123:117-22.
152. **Elkayam U**, Goodwin TM: Adenosine therapy for supraventricular tachycardia during pregnancy. *Am J Cardiol.* 1995; 75:521-23.
153. Keung YK, Lan S, **Elkayam U**, Chen SC, Dourer D: Cardiac arrhythmia after infusion of cryopreserved stern cells. *Bone Marrow Transplantation.*1994; 14:363-7.
154. Mehra A, Shotan A, Ostrzega E, Hsueh W, Johnson J, **Elkayam U**: Potentiation of isosorbide dinitrate effects with n-acetylcysteine in patients with chronic heart failure. *Circulation.*1994; 89:2595-600.
155. Shotan A, Widerhorn J, Hurst A, **Elkayam U**: Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. *Am J Med.* 1994; 96:451- 6.
156. **Elkayam U**: Nitrates in heart failure. *Cardiol Clin.*1994; 12:73-86.
157. Shotan A, Mehra A, Ostrzega E, Hsueh W, Do YS, Fisher DA, Hurst A, Johnson JV, **Elkayam U**: Plasma cyclic guanosine monophosphate in chronic heart failure: Hemodynamic and neurohormonal correlations and response to nitrate therapy. *Clin Pharmacol Ther.* 1993; 54:638-44.
158. Massie BM, Berk MR, Brozena SC, **Elkayam U**, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberger W, Steingart RM, Levine TB, DeHaan H: Can further benefit be achieved by adding a vasodilator to diuretic, digoxin, and angiotensin converting enzyme inhibitor therapy in patients with congestive heart failure? Results of the flosequinan plus ace inhibitor trial (FACET). *Circulation.*1993; 88:492-501.
159. Packer M, Narahara KA, **Elkayam U**, Sullivan JM, Pearle DL, Massie BM, Creager MA and the Principal Investigators of the REFLECT Study: Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. *J Am Coll Cardiol.*1993; 22:65-72.
160. **Elkayam U**, Shotan A, Mehra A, Ostrzega E: Calcium channel blockers in heart failure. *J Am Coll Cardiol.*1993; 22:139A-44A.
161. LeJemtel TH, **Elkayam U**, Costanzo-Nordin MR, Sole M, Factor SM: Peripartum cardiomyopathy: A human model of reversible left ventricular dilatation. *Heart Failure.*1993; 9:63-8.
162. **Elkayam U**, Gleicher N: Congenital heart disease and pregnancy. *Heart Failure.*1993; 9:46-58.
163. Roth A, Shotan A, **Elkayam U**: A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation. *Am Heart J.*1993; 125:155-63.

164. **Elkayam U**, Mehra A, Shotan A, Ostrzega E: Possible mechanisms of nitrates tolerance. *Am J Cardiol.*1992; 70:49G-54G.
165. Mehra A, Ostrzega E, Shotan A, Johnson J, **Elkayam U**: Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic heart failure already treated with captopril. *Am J Cardiol.*1992; 70:1310-14.
166. **Elkayam U**, Mehra A, Shotan A, Ostrzega E: Nitrate resistance and tolerance: potential limitation in the treatment of congestive heart failure. *Am J Cardiol.* 1992; 70:98B-104B.
167. Widerhorn J, Widerhorn ALM, Rahimtoola SH, **Elkayam U**: WPW syndrome during pregnancy: increased incidence of supraventricular tachyarrhythmias. *Am Heart J.*1992; 124:796-98.
168. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, **Elkayam U**, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. *N Engl J Med.* 1991; 325:1468-75.
169. **Elkayam U**, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnson J, Rahimtoola SH: Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. *Circulation.*1991; 84:2040-48.
170. Widerhorn J, Bhandari AK, Bughi S, Rahimtoola SH, **Elkayam U**: Fetal and neonatal adverse effect profile of amiodarone treatment during pregnancy. *Am Heart J.*1991; 122:1162-66.
171. Gollub SB, **Elkayam U**, Young JB, Miller LW, Haffey KA: Efficacy and safety of a short-term (6-H) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled, multicenter study. *J Am Coll Cardiol.* 1991; 18:383-90.
172. **Elkayam U**: Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. *Ann Int Med.*1991; 114:667-77.
173. Iosa D, Dequattro V, Lee DD, **Elkayam U**, Caeiro T, Palmero H: Pathogenesis of cardiac neuro-myopathy in Chagas' disease and the role of the autonomic nervous system. *J Autonomic Nerv Sys.* 1990; 30: S83-8.
174. **Elkayam U**, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. *Circulation.*1990; 82:1954-61.
175. **Elkayam U**, Mehra A. Nitrate tolerance. *Excerpta Médica*, 1990;59-70.
176. **Elkayam U**: Can prognosis be altered by treating LV dysfunction? *Clin Cardiol.*1989; 12: III 58-64.

177. Iosa D, DeQuattro V, De-Ping Lee, **Elkayam U**, Palmero H: Plasma norepinephrine in Chagas' cardiomyopathy: a marker of progressive dysautonomia. *Am Heart J.* 1989; 117:882-7.
178. Jamison M, Widerhorn J, Weber L, Campese V, Vasquez J, Hovanessian L, Rahimtoola SH, **Elkayam U**: Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta₂ adrenoreceptors (dopexamine) in patients with heart failure. *Am Heart J.* 1989; 117:607-14.
179. Kulick D, Roth A, McIntosh N, Rahimtoola SH, **Elkayam U**: Resistance to isosorbide dinitrate in patients with chronic heart failure: incidence and attempt at hemodynamic prediction. *J Am Coll Cardiol.* 1988; 12:1023-28.
180. Kulick DL, Hong R, Rayzen A, Rude RK, Rubin JN, **Elkayam U**, Rahimtoola SH, Bhandari AK: Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease. *Am Heart J.* 1988; 115:367-73.
181. Widerhorn J, Rubin JN, Frishman WI, **Elkayam U**: Cardiovascular drugs in pregnancy. *Cardiol Clinics.* 1987; 5:651-74.
182. **Elkayam U**, Roth A, Kumar A, Kulick D, McKay CR, Rahimtoola SH: Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. *Am J Cardiol.* 1987; 60:1106-11.
183. **Elkayam U**, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH: Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. *Circulation.* 1987; 76:577-84.
184. Rotmensch HH, Rotmensch S, **Elkayam U**: Management of cardiac arrhythmias during pregnancy: current concepts. *Drugs.* 1987; 33:623-33.
185. Kulick D, McIntosh N, Campese VM, Hsueh W, Rahimtoola SH, Massry SG, **Elkayam U**: Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failure. *Am J Cardiol.* 1987; 59:1138-43.
186. Mitani G, Steinberg E, Lien E, Harrison E, **Elkayam U**: The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. *Clinical Pharmacokinetics.* 1987; 12:253-91.
187. Roth A, Kulick D, Freidenberger L, Hong R, Rahimtoola SH, **Elkayam U**: Early tolerance to hemodynamic effects of high-dose transdermal nitroglycerin in responders with severe chronic heart failure. *J Am Coll Cardiol.* 1987; 9:858-64.
188. Roth A, Weber L, Freidenberger L, Rahimtoola SH, **Elkayam U**: Hemodynamic effects of intravenous isosorbide dinitrate and nitroglycerin in acute myocardial infarction and elevated pulmonary artery wedge pressure. *Chest.* 1987; 91:190-6.
189. **Elkayam U**, Roth A, Weber L, Kulick D, Kawanishi D, McKay CR, Rahimtoola SH: Effects of nifedipine on hemodynamics and cardiac function in patients with

normal left ventricular ejection fraction already treated with propranolol. *Am J Cardiol.* 1986; 58:536-40.

190. **Elkayam U**, Roth A, Hsueh W, Weber L, Freidenberger L, Rahimtoola SH: Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. *Am Heart J.* 1986; 111:1130-38.
191. Ryzen E, **Elkayam U**, Rude RK: Low blood mononuclear cell magnesium in intensive cardiac care unit patients. *Am Heart J.* 1986; 111:475-80.
192. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, **Elkayam U**: Efficacy and safety of medium and high-dose diltiazem alone and in combination with digoxin for heart rate control at rest and during exercise in patients with chronic atrial fibrillation. *Circulation.* 1986; 73:316-24.
193. Kawanishi D, McKay CR, Chandraratna PAN, Nanna M, Reid CL, **Elkayam U**, Siegel M, Rahimtoola SH: Cardiovascular response to dynamic exercise in patients with chronic symptomatic mild to moderate and severe aortic regurgitation. *Circulation.* 1986; 73:62-72.
194. **Elkayam U**, Roth A, Weber L, Hsueh W, Nanna M, Freidenberger L, Chandraratna PAN, Rahimtoola SH: Isometric exercise in patients with chronic advanced heart failure: hemodynamic and neurohumoral evaluation. *Circulation.* 1985; 72:975-81.
195. McKay CR, Nanna M, Kawanishi D, **Elkayam U**, Chandraratna PAN, Weiss JN, Rahimtoola SH: Importance of internal controls, statistical methods, and side-effects in short-term trials of vasodilators: a study of hydralazine kinetics in patients with aortic regurgitation. *Circulation.* 1985; 72:865-72.
196. **Elkayam U**, Weber L, McKay C, Rahimtoola SH: Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. *Am J Cardiol.* 1985; 56:560-6.
197. **Elkayam U**, Roth A, Henriquez B, Weber L, Tonnemacher D, Rahimtoola SH: Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic heart failure. *Am J Cardiol.* 1985; 56:555-9.
198. Gardin JM, Tobis JM, Dabestani A, Smith C, **Elkayam U**, Castleman E, White D, Allfie A, Henry WL: Superiority of two-dimensional measurement of aortic vessel diameter in Doppler echocardiographic estimates of left ventricular stroke volume. *J Am Coll Cardiol.* 1985; 6:66-74.
199. **Elkayam U**, Parikh K, Torkan B, Weber L, Cohen JL, Rahimtoola SH: Effect of diltiazem on renal clearance and serum concentration of digoxin in patients with cardiac disease. *Am J Cardiol.* 1985; 55:1393-5.
200. Elrad H, Wall D, Agarwala BN, Stankevych G, **Elkayam U**, Gleicher N: Mother without cardiac history bears second child with heart block. *Hospital Practice.* 1985; 20:100A-100E.

201. **Elkayam U**, Weber L, Campese VM, Massry SG, Rahimtoola SH: Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. *J Am Coll Cardiol.* 1984; 4:1261-7.
202. Rose JS, Nanna M, Rahimtoola SH, **Elkayam U**, McKay C, Chandraratna PAN: Accuracy of determination of changes in cardiac output by transcutaneous continuous wave Doppler computer. *Am J Cardiol.*1984; 54:1099-101.
203. Gleicher N, **Elkayam U**: Cardiac problems in pregnancy. II. Fetal aspects: advances in intrauterine diagnosis and therapy. *JAMA.* 1984; 252:78-80.
204. **Elkayam U**, Weber L, McKay CR, Rahimtoola SH: Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct acting agonism with hydralazine in chronic refractory heart failure. *Am J Cardiol.* 1984; 54:126-31.
205. **Elkayam U**, Gleicher N: Cardiac problems in pregnancy. I. Maternal aspects: the approach to the pregnant patient with heart disease. *JAMA.* 1984; 251:2838-9.
206. **Elkayam U**, McKay CR, Weber L, Eisenberg D, Rahimtoola SH: Favorable effects of hydralazine on the hemodynamic response to isometric exercise in chronic severe aortic regurgitation. *Am J Cardiol.* 1984; 53:1603-7.
207. **Elkayam U**, Weber L, Torkan B, McKay CR, Rahimtoola SH: Comparison of hemodynamic responses to nifedipine and nitroprusside in severe chronic congestive heart failure. *Am J Cardiol.* 1984; 53:1321-5.
208. **Elkayam U**, Wilson AF, Morrison J, Meltzer P, Davis J, Klosterman P, Louvier J, Henry WL: A noninvasive measurement of cardiac output by a single breath constant expiratory technique. *Thorax.* 1984; 39:107-13.
209. Chandraratna PAN, Nanna M, McKay CR, Nimalasuriya A, Swinney R, **Elkayam U**, Rahimtoola SH: Determination of cardiac output by transcutaneous continuous-wave ultrasonic Doppler computer. *Am J Cardiol.* 1984; 53:234-7.
210. **Elkayam U**, Weber L, Torkan B, Berman D, Rahimtoola SH: Acute hemodynamic effects of oral nifedipine in severe chronic congestive heart failure. *Am J Cardiol.* 1983; 52:1041-5.
211. Reid CL, Kawanishi D, Chandraratna PAN, McKay CR, **Elkayam U**, Rahimtoola SH: Accuracy of evaluation of presence and severity of aortic and mitral regurgitation by contrast 2-dimensional echocardiography. *Am J Cardiol.* 1983; 52:519-24.
212. Gardin JM, Iseri LT, **Elkayam U**, Tobis J, Childs W, Burn C, Henry WL: Evaluation of dilated cardiomyopathy by pulsed Doppler echocardiography. *Am Heart J.* 1983; 106:1057-65.
213. **Elkayam U**, Berkley R, Azen S, Weber L, Geva B, Henry WL: Cardiac output by thermodilution technique: effect of injectate volume and temperature on accuracy and reproducibility in the critically ill patient. *Chest.* 1983; 84:418-22.

214. **Elkayam U**, Kawanishi D, Reid CL, Chandraratna PAN, Gleicher N, Rahimtoola S: Contrast echocardiography to reduce ionizing radiation associated with cardiac catheterization during pregnancy. *Am J Cardiol.* 1983; 52:213-4.
215. Tobis JM, Nalcioglu O, Johnston WD, Seibert A, Roeck W, Iseri LT, **Elkayam U**, Henry WL: Correlation of 10-milliliter digital subtraction ventriculograms compared with standard cineangiograms. *Am Heart J.* 1983; 105:946-52.
216. Rozanski A, **Elkayam U**, Berman D, Diamond G, Prause J, Swan HJC: Improvement of resting myocardial asynergy with cessation of upright bicycle exercise. *Circulation.* 1983; 67:529-35.
217. Rotmensch HH, **Elkayam U**, Frishman W: Antiarrhythmic drug therapy during pregnancy. *Ann Int Med.* 1983; 98:487-97.
218. **Elkayam U**, Gardin JM, Berkley R, Hughes C, Henry WL: The use of Doppler flow velocity measurement to assess the hemodynamic response to vasodilators in patients with heart failure. *Circulation.* 1983; 67:377-83.
219. Meltzer P, **Elkayam U**, Parsons K, Gazzaniga A: Esophageal-pericardial fistula presenting as pericarditis. *Am Heart J.* 1983 105:148-50.
220. Tobis JM, Nalcioglu O, Johnston WD, Seibert A, Iseri LT, Roeck W, **Elkayam U**, Henry W: Left ventricular imaging with digital subtraction angiography using intravenous contrast injections and fluoroscopic exposure levels. *Am Heart J.* 1982; 104:20-6.
221. **Elkayam U**, Aronow WS: Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use. *Drugs.* 1982; 23:165-94.
222. Freeman M, Berman D, Staniloff H, **Elkayam U**, Maddahi J, Swan HJC, Forrester J: Comparison of upright and supine bicycle exercise in the detection and evaluation of extent of coronary artery disease by equilibrium radionuclide ventriculography. *Am Heart J.* 1981; 102:182-9.
223. **Elkayam U**, Mathur M, Frishman W, LeJemtel TH, Strom J, Sonnenblick EH: Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. *Clin Pharm Therap.* 1981; 30:23-30.
224. **Elkayam U**, Weinstein M, Berman D, Maddahi J, Staniloff H, Freeman M, Waxman A, Swan HJC, Forrester J: Stress thallium-201 myocardial scintigraphy and exercise technetium ventriculography in the detection and location of chronic coronary artery disease: comparison of sensitivity and specificity of these non-invasive tests alone and in combination. *Am Heart J.* 1981; 101:657-66.
225. Vas R, **Elkayam U**, Meerbaum S: A closed chest animal model for the study of reversible ischemia. *Cardiologia.* 1981; 67:133-47.
226. **Elkayam U**: Vasodilator therapy in primary pulmonary hypertension. *Chest.* 1981; 79:253-4.

227. **Elkayam U**, Frishman W: Appraisal and reappraisal of cardiac therapy. *Am Heart J.* 1980; 397-401.
228. Vas R, Hirsch M, Diamond G, Tzivoni D, Pischler M, **Elkayam U** and Forrester J: Analysis of cardiac kinetics: a use of new photo-optic technique *Am J Physiol.*1980;238(Heart Circ Physiol 7) H98-H106.
229. **Elkayam U**, Aviram A, Blum M, Laniado S: Pericardial involvement in asymptomatic patients undergoing long-term hemodialysis: an echocardiographic study. *Eur J Cardiol.* 1980; 11:445-54.
230. LeJemtel TH, **Elkayam U**, Ribner HS, Hellman C, Strom J, Frishman W, Strobeck J, Sonnenblick EH: Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure. *Eur Heart J.* 1980; 1:157-63.
231. **Elkayam U**, Frishman W: Cardiovascular effects of phenothiazines. *Am Heart J.* 1980; 100:397-401.
232. 20. Rotmensch H, Terdiman R, Cheffer M, **Elkayam U**, Laniado S: Dynamic prognostic profile for acute myocardial infarction. *Chest.*1979; 76:663-7.
233. Frishman w, Silverman R, Strom J, **Elkayam U**, Sonnenblick E: Cardiovascular complications of desipramine overdose: *Cardio Medicine.*1979; 77-79.
234. Geva B, **Elkayam U**, Frishman W, Tradiman R, Laniado S: Correlation of electrocardiography and echocardiography determination of left ventricular wall thickening in patients with chronic systemic hypertension. *Chest.* 1979; 76:557-61.
235. Gleicher N, Knutzen VK, **Elkayam U**, Loew S, Kereny TD: Rheumatic heart disease diagnosed during pregnancy: A 30-year follow-up. *Int J Gyn Obstet.* 1979; 17:51-7.
236. **Elkayam U**, Halprin SL, Frishman W, Strom J, Cohen M: Echocardiographic findings in cardiogenic shock due to right ventricular myocardial infarction. *Cath Cardiovasc Diagnose.* 1979; 5:289-94.
237. **Elkayam U**, LeJemtel T, Mathur M, Ribner H, Frishman W, Strom J, Sonnenblick EH: Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. *Am J Cardiol.* 1979; 44:540-545.
238. Frishman W, Kostis J, Strom J, Hossler M, **Elkayam U**, Goldner S, Silverman R, Davis R, Weinstein J, Sonnenblick EH: Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6, a comparison of pindolol and propranolol in treatment of patients with angina pectoris: the role of intrinsic sympathomimetic activity. *Am Heart J.*1979; 98:526-35.
239. Frishman W, Davis R, Strom J, **Elkayam U**, Stampfer M, Ribner H, Weinstei J, Sonnenblick EH: Clinical pharmacology of the new beta blocking drugs. Part 5, pindolol (LB-46) therapy for supraventricular arrhythmia: a viable alternative to propranolol in patients with bronchospasm. *Am Heart J.* 1979; 98:393-8.

240. Frishman W, Silverman R, Strom J, **Elkayam U**, Sonnenblick EH: Clinical pharmacology of the new beta blocking drugs. Part 4, adverse effects: choosing a beta adrenoreceptor blocker. *Am Heart J.* 1979; 98:256-62.
241. Halprin SL, **Elkayam U**, Frishman W: Aortic stenosis associated with gastrointestinal hemorrhage. *Cardiovasc Med.* 1979; 4:691-2.
242. Frishman W, Factor S, Jordan A, Hellman C, **Elkayam U**, LeJemtel T, Strom J, Unschuld H, Becker R: Right atrial myxoma: unusual clinical presentation and atypical glandular histology. *Circulation.* 1979; 59:1070-5.
243. Geva B, **Elkayam U**, Frishman W, Terdiman R, and Laniado S: Determination of Left Ventricular Wall Thickening in Patients with Chronic Systemic Hypertension: Correlation of Electrocardiography and Echo Cardiography *Chest* 1979; 76:557-61.
244. Strom J, Becker RM, Frishman W, **Elkayam U**, Sonnenblick EH, Feater WH: Effects of hypothermic hyperkalemic cardiopnegeic arrest of ventricular performance during cardiac surgery: assessment of intra-operative echocardiography. *NY State J Med.* 1978; 78:2210-3.
245. **Elkayam U**, Frishman W, Yoran C, Strom J, Sonnenblick EH, Cohen M: Unfavorable hemodynamic and clinical effects of isoproterenol therapy in primary pulmonary hypertension. *Cardiovascular Med.* 1978; 3:1177-1180.
246. **Elkayam U**, Rotmensch HH, Terdiman R, Geller E, Laniado S: Hemodynamic effects of chlorpromazine in patients with acute myocardial infarction and left ventricular failure. *Chest.* 1977; 72:623-7.
247. **Elkayam U**, Weiss S, Laniado S: Pericardial effusion and mitral valve involvement in systemic lupus erythematosus: an echocardiographic study. *Ann Rheum Dis.* 1977:36:349-53.
248. **Elkayam U**, Kotler MN, Segal B, Parry W: Echocardiographic findings in constrictive pericarditis: a case report. *Israel J Med Sci.* 1976; 12:1308-12.
249. **Elkayam U**, Laniado S: Echocardiography of the mitral valve: clinical aspects. *Harefuah.* 1976; 91:285-290.
250. **Elkayam U**, Laniado S: The use of nitroglycerin in acute myocardial infarction. *Harefuah.* 1976; 91:250-2.
251. Geller E, **Elkayam U**, Terdiman R, Meytes I, Laniado S: Bedside hemodynamic evaluation with the aid of a desk computer. *Harefuah Journal of the Israel Medical Association.* 1976; 90:421-4.

ABSTRACTS

1. Ng TMH, Peterson EJ, Patel KA, Lou M, Huang G, **Elkayam U**. Nadir, Not Admission, Serum Albumin is Associated with Increased Risk of Acute Worsening of Renal Function in Acute Heart Failure. *J Card Fail* 2013;19(8 suppl): S9.
2. Ng TMH, Hshieh S, Chan CY, **Elkayam U**. Clinical experience with low dose continuous infusion furosemide in acute heart failure: assessment of efficacy and safety. *J cardiac Fail* 2011;17: S66.
3. McNamara D, **Elkayam U**, Cooper LT, Pisarcik J, Gorcsan J, Echelbert EB, McTierman C, Fett JD. Design of the Investigations in pregnancy associated cardiomyopathy (IPAC) trial: A Multicenter investigation of immune pathogenesis and myocardial recovery in peripartum cardiomyopathy. *J Cardiac Fail* 2011;17: S59.
4. Ng TMH, Kim BJ, Park JI, Louie SG, **Elkayam U**. Adrenergic mediated suppression of monocyte proinflammatory cytokine production is reduced in Acute Heart Failure. *J Cardiac Fail* 2011;17: S29.
5. Lieu HD, Young J, **Elkayam U**, Katz A, Darius H, Goldstein S, Massie B, Costello-Boerrigter L, Burnett J. A phase II, dose ranging study with CD-NP, a chimeric natriuretic peptide, in acute decompensated heart failure patients with renal compromise. *J Am Coll Cardiol*. 2011; 57: E2029.
6. Ng TM, Konopka E, Hyderi AF, Hsieh S, Tsuji Y, Kim BJ, Han SY, Phan DH, Jeng AI, Lou M, **Elkayam U**. Comparison of the efficacy and safety of various diuretic regimens used to overcome diuretic resistance in acute heart failure. *J AM Coll Cardiol*. 2011; 57: E215.
7. Fan J, Goland S, Khatri N, **Elkayam U**. Monitoring of anti Xa in pregnant patients with mechanical prosthetic valves receiving low molecular weight heparin: peak or trough levels? *Circulation* 122: A18219.
8. Goldsmith SR, **Elkayam U**. A dose ranging pilot study of conviptan in acute decompensated heart failure. *Circulation*. 2006; 114: II_570.
9. Goland S, Bitar F, Modi K, Akter MW, Janmohamed M, Hatamizadeh P, **Elkayam U**. Clinical Profile and Risk Predictors of Major Adverse Events in Patients with Peripartum Cardiomyopathy *Circulation*, 2006; 114: II_622.
10. Mod Ki, Bitar F, Goland S, Jariatul K, Illum S, Akhter MW, Khan S, Raymundo B, **Elkayam U**: Left ventricular size and function at diagnosis the only predictor of failure to recover in peripartum cardiomyopathy. *Circulation*, 2005; 112: II_542
11. Citania L Tedoldi CL, Bordignon s, Rio Grande, Caetano ME, Bel Sebastiao AM, Clapauch SH, Uri **Elkayam**: Adverse outcomes in pregnant women with prosthetic heart valve: a risk analysis. *Circulation*, 2005; 112: II 716.

12. **Elkayam U.** Nesiritide May Diminish the Increased Acute Mortality Risk Associated with Worsening Renal Failure. *Circulation*, 2005; 112: II_675.
13. **Elkayam U,** Ng TM, Mehra AO, Garty M: Magnitude of Effect and site of Action of Dopamine on the Renal Circulation in Patients with Severe Heart Failure. *J Card Fail* 2005; 11:6 (Suppl).
14. O'Connor C, Adams K, Gattis W, Barbagelata A, **Elkayam U,** McGrew F, Ghali J, Benza R, Klapholz M, Ouyang J, Orlandi C, Gheorghiadu M: Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF trial. *J Am Coll Cardiol* 2004;43 (Suppl. A): 181A.
15. **Elkayam U,** Akhter M, Shotan A, Hameed A, Singh H, Khan S, Usman A, Khan M: Pregnancy Associated Cardiomyopathy: Clinical Profile in 137 Patients Diagnosed in the United States. *J Am Coll Cardiol* 2003; 41:6 (Suppl. A) 184A.
16. **Elkayam U,** Akhter M, Shotan A, Hameed A, Singh H, Khan S, Usman A, Khan M: Pregnancy-Associated Cardiomyopathy: Early Versus Late Presentation. *J Am Coll Cardiol* 2003; 41:6 (Suppl. A) 151A.
17. **Elkayam U:** Renal insufficiency as a predictor of predictor of cardiovascular outcome in hospitalized patients with decompensated heart failure. *J Am Coll Cardiol* 2002; 39 (Suppl. A): 184A.
18. **Elkayam U,** Kim J, Currie AM, Margolis J: Prevalence of anemia and anemia treatment in patients with congestive heart failure. Presented at the American Heart Association 4th Scientific Forum on Quality of Care Outcome Research in Cardiovascular Disease and Stroke.
19. **Elkayam U,** Prakash M, Subbiah S, Mehdi S, Nikitina A, Akhter W: Endothelial function in patients with chronic heart failure. *J Cardiovasc Pharmacol.* 2001; 38 Suppl 2: S47-8.
20. **Elkayam U,** on Behalf of the VMAC Study Group: The lack of ischemic cardiovascular adverse events with nesiritide (B-type natriuretic peptide) and nitroglycerin in the treatment of acute heart failure. *J Cardiac Failure* 2001; 7(Suppl 2): 59.
21. **Elkayam U,** on Behalf of the VMAC Study Group: Limitations of commonly used titrated doses of intravenous nitroglycerin in patients with acute decompensated heart failure. *J Cardiac Failure* 2001;7(Suppl 2): 12.
22. Canetti M, Lerman A, Karaalp IS, Akhter WM, Mehra S, **Elkayam U:** Abnormal Coronary blood flow Reserve in Idiopathic Dilated Cardiomyopathy is due to impairment of both Endothelium-Dependent and Independent Microrcirculatory Vasodilation. *J Am Coll Cardiol* 37 (Suppl. A): 187A, 2001.
23. Burger AJ, Horton DP, **Elkayam U,** LeJemtel T, Ghali J: Evidence of Ventricular Ectopy at Baseline Is Not Predictive of the Proarrhythmic Effects of Dobutamine in the Treatment of Decompensated CHF: The PRECEDENT study. *J Cardiac Failure* 2000; 6:46.

24. Burger AJ, Horton DP, **Elkayam U**, LeJemtel T, Ghali JK: Comparison of the Effects of Dobutamine and Nesiritide (B-Type Natriuretic Peptide) on Cardiac Ectopy in Acutely Decompensated Ischemic versus Non-Ischemic Cardiomyopathy. *J Cardiac Failure* 6:49, 2000.
25. **Elkayam U**, Silver MD, Burger AJ, Horton DP: The Effect of Short Term Therapy with Nesiritide (B-Type Natriuretic Peptide) or Dobutamine on Long Term Survival. *J Cardiac Failure* 2000; 6:44
26. Burger AJ, Horton DP, **Elkayam U**, LeJemtel TH, Ghali J: Nesiritide is not associated with the proarrhythmic effects of dobutamine in the treatment of decompensated CHF: the PRECEDENT study. *Circulation* 1999; 100(18), I-647.
27. Tummala PP, Rao KS, Akhter MW, Karaalp IS, Hameed AB, **Elkayam U**: Peripartum cardiomyopathy: clinical profile of 100 patients diagnosed in the United States. *Circulation* 1999; 100: I-579.
28. Tummala PP, Akhter MW, Hameed AB, Karaalp IS, Rao KS, Johnson JV, **Elkayam U**: Risk of subsequent pregnancies in women with a history of peripartum cardiomyopathy. *Circulation* 1999; 100: I-381.
29. Hameed AB, Wani OR, Karaalp IS, Tummala PP, Canetti M, Goodwin M, **Elkayam U**: Valvular disease in pregnancy: effects on maternal and fetal outcome. *Circulation* 1999; 100: I-148.
30. **Elkayam U**, Johnson JV, Shotana, Bokhauri S, Solodky A, Canetti M, Wani OR, Karaalp I S: Intermittent large dose nitrates added to standard therapy, improves left ventricular function and exercise capacity in patients with chronic heart failure. *J Am Coll Cardiol* 1999; 33: 188A.
31. **Elkayam U**, Neibam M, Haught H, Horton D: Safety study of nisiritide (human b-type natriuretic peptide) for the treatment of hospitalized patients with acutely decompensated CHF. *J Cardiac Failure* 1998; 4:(Suppl. 1): 40.
32. Silver MA, Ghali JK, Horton D, **Elkayam U**: Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure. *J Cardiac Failure* 1998; 4 (Suppl. 1): 40
33. **Elkayam U**, Mehra A, Kauffman JY, Gogia H, Bokhari S, Tummala PP: Attenuation of acetylcholine mediated coronary vasoconstriction with nonvasodilating dose of nitroglycerin in patients with heart failure: Evidence for nitroglycerin induced enhancement of endogenous nitric oxide effect? *J Am Coll Cardiol* 1998;31: 460A.
34. **Elkayam U**, Canetti M, Karaalp IS, Wani O, Gogia H, Kauffman J, Mehra A: Pulmonary circulatory response to endothelial stimulation in patients with chronic heart failure. *J Am Coll Cardiol* 1998; 31: 432A.
35. Mehra A, Cohen G, Johnson JV, **Elkayam U**: Effect of adenosine on the renal circulation in patients with chronic heart failure. *J Am Coll Cardiol* 1997; 29 (Suppl. A): 370A,

36. **Elkayam U**, Hurst A, Shotan A, Hoffman-Willey K, Johnson J, Koda R: Evidence for attenuated heart rate control with beta blockade in women with heart disease during pregnancy: A pharmacokinetic and pharmacodynamic study. *J Am Coll Cardiol* 1996;27(Suppl. A): 79A.
37. **Elkayam U**, Gadallah S, Mehra A, Vallabhaneni R, Johnson JV: Evaluation of magnitude of effect and site of action of dopamine on the renal circulation in patients with heart failure with the aid of intravascular ultrasound and Doppler techniques. *J Am Coll Cardiol* 1996; 27(Suppl. A): 338A.
38. Ostrzega E, **Elkayam U**: Risk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy: Results of a Survey. *Circulation*1995; 92 (Suppl. I): I-333.
39. Hurst AK, Shotan A, Hoffman-Willey K, Johnson J, Koda R, Goodwin TM, **Elkayam U**: Pharmacokinetics (PK) and heart rate control with atenolol during and after pregnancy. *Pharmacotherapy* 1995;15 (3): 364.
40. Hurst AK, Shotan A, Hoffman-Willey K, Goodwin TM, Johnson J, Koda R, **Elkayam U**: Heart rate control on beta adrenoreceptor blocking therapy during pregnancy in patients with cardiac disease. *J Invest Med* 1995; 43 (Suppl. 2): 321A.
41. **Elkayam U**, Cohen G, Gogia H, Mehra A, Chandraratna PAN, Johnson JV: The effect of endothelial stimulation on the renal circulation in patients with chronic heart failure. *J Am Coll Cardiol* 1995; 25: 297A.
42. Gogia H, Mehra A, Parikh S, Ajit-Uppal J, Johnson JV, **Elkayam U**: A randomized study to evaluate the effect of hydralazine on the development of nitrate tolerance in patients with heart failure. *Circulation* 90: I-601, 1994.
43. **Elkayam U**, Goodwin TM: Safety and efficacy of intravenous adenosine therapy for supraventricular tachycardia during pregnancy: Results of a national survey. *J Am Coll Cardiol*, 1994; 23:91A.
44. **Elkayam U**, Shotan A, Mehra A, Ostrzega E: Calcium Channel Blockers in Heart Failure. *J Am Coll Cardiol* 1993; 22 (Suppl. A): 139A.
45. Mehra A, Shotan A, Kawanishi D, Ostrzega E, Vasquez-Johnson J, **Elkayam U**: Reduction in mitral valve regurgitant area secondary to left ventricular remodeling: A mechanism for improvement of mitral regurgitation mediated by vasodilator therapy. *J Am Coll Cardiol* 1993; 21 (Suppl. A): 352A.
46. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, **Elkayam U**: Overcoming early nitrate tolerance with escalating oral dose of isosorbide dinitrate in chronic heart failure. *J Am Coll Cardiol* 1993; 21 (Suppl. A): 252A.
47. Ostrzega E, Mehra A, Widerhorn J, Shotan A, Johnson J, Rahimtoola SH, **Elkayam U**: Evidence for increased incidence of arrhythmias during pregnancy: A study of 104 pregnant women with symptoms of palpitations, dizziness or syncope. *J Am Coll Cardiol* 1992;19(3) (Suppl. A): 125A.

48. Widerhorn J, Riggio D, Bhandari AK, Rahimtoola SH, **Elkayam U**: Risk stratification of patients with nonischemic congestive cardiomyopathy and nonsustained ventricular tachycardia. *Circulation* 1992; 86: I-395.
49. Massie BM, Berk MR, Brozana S, **Elkayam U**, Plehn J, Kukim M, Murphy B, Neuberg G, Steingart R, DeHaan H for the FACET investigators: Can further benefit be achieved by adding a vasodilator to triple therapy in CHF: Results of the flosequinan-ACE inhibitor trial (FACET). *Circulation* 1992; 86: I-645.
50. Shotan A, Ostrzega E, Mehra A, Johnson J, **Elkayam U**: Reduction plasma cyclic guanosine monophosphate in patients with chronic heart failure and reduction following nitrate therapy. *Circulation* 1991;84(4): II-57.
51. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Potentiation of nitrate effect does occur after sulfhydryl groups supply in heart failure patients treated with isosorbide dinitrate. *Circulation* 1991; 84(4): II-57.
52. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Hemodynamic benefit of nitrate therapy in patients with heart failure already treated with angiotensin converting enzyme inhibition. *J Am Coll Cardiol* 1991;7: 163A.
53. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Overcoming early nitrate tolerance with escalating oral dose of isosorbide dinitrate in chronic heart failure. *Clin Res* 1991; 39: 121A.
54. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Beneficial effect of nitrate therapy in patients with heart failure already treated with captopril. *Clin Res* 1991; 39: 120A.
55. Mehra A, Ostrzega E, Widerhorn J, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Arrhythmias in pregnancy: prevalence and effect on fetal and maternal outcome in a large group of symptomatic women. *Clin Res* 1991; 39: 79A.
56. Mehra A, Ostrzega E, Shotan A, Vasquez-Johnson J, Rahimtoola SH, **Elkayam U**: Can captopril prevent nitrate tolerance in patients with heart failure? *Clin Res* 1991; 39:49A.
57. Packer M, Narahara KA, **Elkayam U**, Sullivan JM, Pearly DL, Massie BM, Creager MA: Randomized, multicenter, double-blind, placebo-controlled study of the efficacy of flosequinan, a new, long-acting vasodilator drug, in patients with chronic heart failure. *Circulation* 1990; 82(Suppl III): 323.
58. **Elkayam U**, Amin J, Mehra A, Vasquez J, Weber L, Jamison M, Rahimtoola SH: Effect of nifedipine, isosorbide dinitrate and their combination on exercise tolerance and clinical status in chronic heart failure. *Circulation* 1989; 80(Suppl II): 252,
59. **Elkayam U**, Jamison M, Roth A, Kulick D, Vasquez J, Rahimtoola SH: Oral isosorbide dinitrate in chronic heart failure: tolerance development to QID vs TID regimen. *J Am Coll Cardiol* 1989; 13: 178A.

60. **Elkayam U**, Jamison M, Roth A, Kulick D, Vasquez J, Weber L, Rahimtoola SH: Hemodynamic tolerance to oral isosorbide dinitrate in chronic heart failure: should the drug be given every 6 hours? Clin Res 1989; 7: 93A.
61. Jamison M, Widerhorn J, Weber J, Campese V, **Elkayam U**: Central and renal hemodynamic effects of a new agonist at peripheral dopamine and beta receptors (dopexamine) in heart failure. Circulation 1988; 78(Suppl II): 624.
62. **Elkayam U**, Roth A, Rahimtoola SH: Isometric exercise mediated hemodynamic worsening and its prevention with nitroglycerin in patients with chronic mitral regurgitation. J Am Coll Cardiol 1988; 11: 230A.
63. Kulick D, Bhandari A, Hong R, Petersen R, **Elkayam U**, Rahimtoola SH: Programmed ventricular stimulation in patients with dilated cardiomyopathy: effect of hemodynamic instability on inducibility of ventricular arrhythmias. J Am Coll Cardiol 1988; 11: 72A.
64. Kotlewski A, McKay CR, Harrison EC, Kawanishi DT, Reid C, Chandraratna PAN, Bhandari A, **Elkayam U**, Niland J, Rahimtoola SH: Incremental value of clinical examination, echocardiography and cardiac catheterization in the evaluation of left ventricular dysfunction and pulmonary hypertension in valvular heart disease. J Am Coll Cardiol 1988; 11: 64A.
65. Kulick D, Hong R, Ryzen E, Rude R, **Elkayam U**, Rahimtoola SH, Bhandari A: Electrophysiologic effects of intravenous magnesium sulfate in patients with no apparent heart disease. Clin Res 1988; 35:110A.
66. **Elkayam U**, Roth A, Kulick D, McIntosh N, Weber L, Rahimtoola SH: A comparison between amrinone and nitroprusside: a clinical evidence for positive inotropic effect of amrinone in patients with severe heart failure. Clin Res 1988; 5: 106A.
67. **Elkayam U**, Kulick D, Roth A, McIntosh N, Weber L, Rahimtoola SH: Early tolerance to oral nitrate therapy in patients with chronic heart failure: effect of dosing intervals. Circulation 1987; 76(Suppl IV): 256.
68. Kulick D, Roth A, McIntosh N, **Elkayam U**: Resistance to isosorbide dinitrate in patients with chronic heart failure: incidence and attempt at hemodynamic prediction. Circulation 1987; 76(Suppl IV): 177.
69. Roth A, Rahimtoola S, **Elkayam U**: Enhancement of hemodynamic effects of hydralazine with nitroglycerin in patients with chronic mitral regurgitation. Circulation 1987; 76(Suppl IV): 89.
70. Kotlewski A, McKay CR, Harrison EC, Kawanishi DT, Reid CL, Chandraratna PAN, Bhandari A, **Elkayam U**, Niland J, Rahimtoola SH: Incremental value of clinical examination echocardiography and cardiac catheterization in the evaluation of mitral valve disease. Circulation 1987; 76(Suppl IV): 88,
71. Roth A, Campese VM, Hsueh W, McIntosh N, Rahimtoola SH, **Elkayam U**: Failure of intravenous amrinone to improve renal hemodynamics and neurohumoral status in patients with severe chronic heart failure. J Am Coll Cardiol 1987; 9: 103A.

72. **Elkayam U**, Kulick D, McIntosh N, Roth A, Rahimtoola SH: Incidence of early tolerance to continuous intravenous nitroglycerin infusion in patients with coronary artery disease and heart failure. *J Am Coll Cardiol* 1987; 9: 103A.
73. **Elkayam U**, Roth A, Weber L, Rahimtoola SH: Nitrate Resistance: Failure of intravenous nitrate to reduce elevated left ventricular filling pressure in acute myocardial infarction, a common and unpredictable phenomenon. *J Am Coll Cardiol* 1987; 9: 23A.
74. Roth A, Campese VM, Hsueh W, McIntosh N, Rahimtoola SH, **Elkayam U**: Effects of intravenous amrinone on renal hemodynamics and neurohumoral status in patients with severe chronic heart failure. *Clin Res* 1987; 35: 113A.
75. Kulick D, Roth A, McIntosh N, Rahimtoola SH, **Elkayam U**: Resistance to isosorbide dinitrate in patients with chronic heart failure: incidence and attempt at hemodynamic prediction. *Clin Res* 1987; 35: 109A.
76. Kulick D, McIntosh N, Hsueh W, Campese V, Rahimtoola SH, **Elkayam U**: Diltiazem in patients with severe left ventricular systolic dysfunction: evaluation of central and renal hemodynamic response. *Clin Res* 1987;35: 108A.
77. **Elkayam U**, Roth A, Kumar A, Kulick D, McKay CR, Rahimtoola SH: Hemodynamic and volumetric effects of nitroglycerin in chronic severe mitral regurgitation. *Clin Res* 1987; 35: 103A.
78. Roth A, Freidenberger L, Baruch T, Rahimtoola SH, **Elkayam U**: Hemodynamic effects of nitrate therapy during isometric exercise in patients with chronic heart failure. *J Am Coll Cardiol* 1986; 7: 233A.
79. Roth A, Kumar A, Kulick D, McKay CR, Kawanishi D, Rahimtoola SH, **Elkayam U**: Beneficial effects of nitrate therapy on left ventricular hemodynamics and function in patients with chronic severe mitral regurgitation. *J Am Coll Cardiol* 1986; 7: 170A.
80. Roth A, Harrison E, Mitani G, Freidenberger C, Rahimtoola SH, **Elkayam U**: Diltiazem vs digoxin for heart rate control in patients with chronic atrial fibrillation. *J Am Coll Cardiol* 1986; 7: 69A.
81. Roth A, Kulick D, Freidenberger L, Hong R, Rahimtoola SH, **Elkayam U**: Early tolerance to hemodynamic effects of sustained nitrate therapy with high-dose Transdermal nitroglycerin in patients with severe chronic heart failure. *J Am Coll Cardiol* 1986; 7: 27A.
82. Roth A, Henriquez B, Weber L, Freidenberger L, Rahimtoola SH, **Elkayam U**: Intravenous isosorbide dinitrate in acute myocardial infarction and pump failure: investigation of dose requirement, magnitude and persistence of effects and hemodynamic rebound. *Clin Res* 1986; 34: 13A.
83. McKay CR, Nanna M, Reid CL, Kawanishi D, Stiles Q, **Elkayam U**, Rahimtoola SH: Superiority of aortic valve replacement over arteriolar dilator therapy for symptomatic chronic severe aortic regurgitation. *Clin Res* 1986; 4: 12A.

84. Au P, McKay CR, Kotlewski D, **Elkayam U**, Tonnemacher D, Weiss J, Reid CL, Chandraratna PAN, Rahimtoola SH: Error of thermodilution cardiac output measurements in severe tricuspid regurgitation. *Clin Res* 1986; 34: 3A.
85. **Elkayam U**, Roth A, Weber L, Kawanishi D, McKay CR, Rahimtoola SH: The effect of nifedipine on cardiac hemodynamics and performance in patients with chest pain already treated with propranolol. *Chest* 1985; 88: 355.
86. **Elkayam U**, Weber L, Roth A, Hsueh W, Rahimtoola SH: Isometric exercise in severe chronic heart failure: hemodynamic and hormonal response and effect of arterial dilation with hydralazine. *J Am Coll Cardiol* 1985; 5: 460.
87. **Elkayam U**, Parikh K, Torkan B, Weber L, Cohen JL, Rahimtoola SH: Absence of Effect of diltiazem on digoxin serum concentration and renal clearance in patients with cardiac disease. *J Am Coll Cardiol* 1985; 5: 419.
88. **Elkayam U**, Roth A, Hsueh W, Weber L, Freidenberger L, Rahimtoola SH: Neurohumoral changes following arterial dilation with hydralazine and nifedipine in heart failure. *Clin Res* 1985; 33: 88A.
89. **Elkayam U**, Parikh K, Torkan B, Weber L, Cohen JL, Rahimtoola SH: Lack of interaction between diltiazem and digoxin in patients with heart disease. *Clin Res* 1985; 33: 88A.
90. **Elkayam U**, Henriquez B, Weber L, Tonnemacher D, Rahimtoola SH: Lack of hemodynamic effect of high dose transdermal nitroglycerin in severe heart failure. *Circulation* 1984; 70: 454.
91. Kawanishi D, McKay CR, Chandraratna PAN, Nanna M, Reid CL, **Elkayam U**, Siegel M, Rahimtoola SH: Cardiovascular response to dynamic exercise in symptomatic patients with chronic severe aortic regurgitation. *J Am Coll Cardiol* 1984; 3: 534.
92. **Elkayam U**, Weber L, Campese V, Massey S, Rahimtoola SH: Acute effect of arterial vasodilation with nifedipine on renal hemodynamics in patients with severe chronic heart failure. *J Am Coll Cardiol* 1984; 3: 479.
93. **Elkayam U**, Weber L, McKay CR, Rahimtoola SH: Variable, unpredictable and deleterious hemodynamic response to oral nifedipine in severe chronic heart failure: an experience in 32 patients. *J Am Coll Cardio* 1984; 3: 478.
94. Rose J, Chandraratna PAN, McKay CR, **Elkayam U**, Nanna M, Nimalasuriya A, Rahimtoola SH: Accuracy of determination of changes in cardiac output by transcutaneous continuous wave ultrasound Doppler computer. *Circulation* 1983; 68(Suppl III): 367.
95. **Elkayam U**, Weber L, Rose J, McKay CR, Rahimtoola SH: Nifedipine vs hydralazine in the treatment of severe heart failure: an evidence for a negative inotropic effect of nifedipine. *Circulation* 1983; 68(Suppl III): 8.

96. McKay CR, Nanna M, Kawanishi D, **Elkayam U**, Rahimtoola SH: Hydralazine dose determines duration of effect in chronic aortic regurgitation. *Circulation* 1983; 68(Suppl III): 340.
97. McKay CR, Nanna M, **Elkayam U**, Kawanishi D, Chandraratna PAN, Rahimtoola SH: Long-term vasodilator treatment of chronic aortic regurgitation, preliminary evidence of hemodynamic and functional improvement. *Circulation* 1983; 68(Suppl III): 300.
98. **Elkayam U**, McKay CR, Weber L, Torkan B, Eisenberg D, Berman D, Rahimtoola SH: The effects of hydralazine on hemodynamic response to isometric exercise in patients with chronic aortic insufficiency. *Clin Pharm Therap* 1983; 33: 204.
99. **Elkayam U**, Weber L, Torkan B, Rahimtoola SH: Hemodynamic effects of nifedipine in chronic heart failure. *Clin Pharm Therap* 1983; 33: 204.
100. **Elkayam U**, Weber L, Torkan B, Berman D, Rahimtoola SH: Hemodynamic effects of nifedipine in patients with severe chronic congestive heart failure. *Clin Res* 1983; 31: 19A.
101. McKay CR, Nanna M, Kawanishi D, **Elkayam U**, Rahimtoola SH: Duration of hemodynamic effects of hydralazine in chronic aortic regurgitation: a function of dose. *Clin Res* 1983; 31:14A.
102. Kawanishi D, McKay CR, Chandraratna PAN, Nanna M, **Elkayam U**, Reid C, Siegel M, Rahimtoola SH: Circulatory response to exercise in patients with chronic aortic regurgitation: a decrease in aortic regurgitation. *Clin Res* 1983; 31:11A.
103. Gardin JM, Tobis JM, Dabestani A, Smith C, **Elkayam U**, Castlemen E, Allfie A, Henry WL: Superiority of two-dimensional measurement of aortic vessel diameter in Doppler echocardiographic estimates of left ventricular stroke volume. *Clin Res* 1983; 31:8A.
104. **Elkayam U**, Weber L, Torkan B, Berman D, Rahimtoola SH: Intravenous nitroprusside is superior to oral nifedipine in the acute treatment of patients with severe congestive heart failure. *Clin Res* 1983; 31:7A.
105. **Elkayam U**, McKay C, Weber L, Torkan B, Eisenberg D, Berman D, Rahimtoola SH: Beneficial effects of oral hydralazine on hemodynamic response to isometric exercise in patients with chronic aortic insufficiency. *Clin Res* 1983; 31:6A.
106. Tobis J, Nalcioglu O, Seibert JA, Roeck WW, Iseri LT, **Elkayam U**, Johnston W, Henry WL: Digital intravenous angiography: a new technique for obtaining ventriculograms following intravenous injection of iodinated contrast material. *Am J Cardiol* 1982; 49:985
107. **Elkayam U**, Gardin JM, Berkley R, Hughes CA, Henry WL: Use of Doppler blood flow velocity measurements to evaluate the response of systemic vascular resistance to vasodilators in patients with congestive heart failure. *Am J Cardiol* 1982; 9:943
108. Johnston WD, Tobis J, Nalcioglu O, Seibert A, Roeck WW, Iseri LT, **Elkayam U**, Henry WL: End-diastolic mask subtraction: an improved method for displaying wall

- motion abnormalities using a digital angiography computer system. *Am J Cardiol* 1982; 49:935
109. Tobis J, Nalcioğlu O, Seibert A, Roeck W, Iseri L, **Elkayam U**, Johnston W, Henry W: Digital intravenous angiography: a new technique for obtaining ventriculogram following intravenous injection of iodinated contrast material. *Clin Res* 1982; 30:22A.
 110. **Elkayam U**, Gardin JM, Berkley R, Hughes CA, Henry WL: The use of Doppler flow velocity measurement to assess vasodilator induced changes in stroke volume and systemic vascular resistance. *Clin Res* 1982; 30:7A.
 111. Tobis JM, Nalcioğlu O, Seibert JA, Roeck WW, Iseri LT, **Elkayam U**, Johnston WD, Henry WL: Use of digital angiography in assessment of ventricular ejection fraction and pacing induced wall motion abnormalities. *Circulation* 1981; 64(Suppl IV): 250.
 112. **Elkayam U**, Wilson A, Morrison J, Davis J, Klosterman P, Salness K, Louvier J, Henry WL: A non-invasive assessment of cardiac output by a single breath technique. *Circulation* 1981; 64(Suppl IV): 300.
 113. **Elkayam U**, Gardin J, Berkley R, Hughes C, Henry WL: The value of aortic flow measurements using Doppler technique for the quantitative assessment of changes in stroke volume. *Circulation* 1981; 64(Suppl IV): 256.
 114. Tobis J, Iseri L, **Elkayam U**, Udall J, Gardin J, Henry W: Angulated coronary angiogram in the long axis view. *Clin Res* 1981; 29:246A.
 115. **Elkayam U**, Wilson A, Davis J, Klosterman P, Louvier J, Morrison J, Henry WL: An evaluation of a new single breath technique for a non-invasive assessment of cardiac output. *Clin Res* 1981; 29:445A.
 116. **Elkayam U**, Mumford M, Tobis J, Henry W: Thermodilution cardiac output determination: the effect of injectate volume and temperature on accuracy and reproducibility. *Clin Res* 1981; 29:188A.
 117. Gardin JM, Iseri LT, **Elkayam U**, Tobis J, Childs W, Burn CS, Henry WL: Use of Doppler echocardiography in the non-invasive assessment of left ventricular dysfunction in patients with dilated cardiomyopathy. *Circulation* 1980; 62: III-200.
 118. Freeman M, Berman D, Maddahi J, Staniloff H, **Elkayam U**, Pantaleo N, Waxman A, Forrester J, Swan HJC: Comparison of upright and supine exercise of scintigraphic ventriculography in patients with suspected coronary artery disease. *Clin Res* 1980; 28:170A.
 119. Berman D, Pantaleo N, **Elkayam U**, Freeman M, Staniloff H, Maddahi J, Garcia E, Waxman A, Forrester J, Swan HJC: Scintigraphic assessment of latent mechanical function: comparison of regional and global ventricular responses immediately after upright exercise following nitroglycerin. *Clin Res* 1980; 28:157A.

120. Staniloff HM, Diamond G, Berman DS, Freeman MR, **Elkayam U**, Waxman A, Forrester JS: An integrated format for multiple testing in coronary artery disease. *Am J Cardiol* 1980; 45:463
121. Maddahi J, Berman D, Freeman M, **Elkayam U**, Staniloff H, Pantaleo N, Forrester J, Swan HJC, Waxman A: Simultaneous assessment of right and left ventricular responses to exercise using multiple gated equilibrium scintigraphy: increased accuracy for evaluation of the extent of coronary artery disease. *J Nuclear Med* 1979; 20:625.
122. Staniloff H, Diamond G, Hirsch H, Berman D, Charuzi Y, Freeman M, **Elkayam U**, Vas R, Waxman A, Forrester J: Sequential bayesian analysis of multiple non-invasive tests for the accurate detection of coronary artery disease. *J Nuclear Med* 1979; 20:651.
123. **Elkayam U**, Mathur M, LeJemtel T, Frishman W, Strom J, Sonnenblick EH: Comparative hemodynamic effects of oral prazosine and hydralazine in refractory heart failure. *Clin Res* 1979; 27:163A.
124. Freeman M, Pichler M, Berman D, Shah PK, Maddahi J, Waxman A, Staniloff H, **Elkayam U**, Anderson A, Swan HJC: Improved non-invasive assessment of segmental wall motion in acute myocardial infarction by an additional 70-degree LAO view in multiple gated equilibrium scintigraphy. *Clin Res* 1979; 27:3A.
125. Staniloff H, Berman D, **Elkayam U**, Freeman M, Diamond G, Waxman A, Drake D, Forrester J: Equilibrium nuclear probe for the measurement of left ventricular ejection fraction: detailed analysis of effects of mode of acquisition and observer variation. *Clin Res* 1979; 27:12A.
126. **Elkayam U**, Berman D, Maddahi J, Diamond G, Charuzi Y, Waxman A, Stanilof H, Freeman M, Vas R, Forrester J: Combination of exercise TL-201 myocardial scintigraphy and TC-99M RBC wall motion study: a useful noninvasive predictor of extent and location of coronary arterial disease. *Clin Res* 1979; 27:3A.
127. **Elkayam U**, LeJemtel T, Mathur M, Ribner H, Frishman W, Strom J, Sonnenblick EH: Marked early attenuation of hemodynamic effect of oral prazosin therapy in chronic congestive heart failure. *Am J Cardiol* 1979; 43:403
128. Frishman W, Strom J, Davis R, **Elkayam U**, Weinstein J, Sonnenblick EH: Efficacy of a new beta-adrenergic blocking agent (pindolol) in the acute and chronic therapy of supraventricular arrhythmias. *Am J Cardiol* 1979; 43:431
129. Ribner H, LeJemtel T, **Elkayam U**, Weinstein J, Sonnenblick EH: Relationship between initial systemic vascular resistance and the response to vasodilators in severe chronic congestive heart failure. *Am J Cardiol* 1979; 43:404
130. Becker RM, Strom J, **Elkayam U**, Frishman W, Frater RWM, Sonnenblick EH: Effects of hypothermic hyperkalemic cardioplegic arrest of ventricular performance during cardiac surgery assessment by intraoperative echocardiography. *Ann Royal Coll Phys Surg, Canada* 1978; 11:32.

131. Frishman W, Strom J, **Elkayam U**, LeJemtel T: LB-46 therapy in supraventricular arrhythmia: a viable alternative to propranolol in patients with bronchospastic disease. Bulletin NY Acad Med 1978; 54:315.
132. Strom J, Frishman W, **Elkayam U**, LeJemtel T, Ribner H, Strobeck J, Stein J, Sonnenblick EH: Pre- and post-exercise echocardiography in evaluating ischemic ECG changes in patients without chest pain. Circulation 1977; 56(Suppl III): 198.
133. Frishman W, Stampfer M, Strom J, **Elkayam U**, LeJemtel T, Weinstein J, Sonnenblick EH: Pindolol (LB-46) therapy for supraventricular arrhythmia: a viable alternative to propranolol in patients with bronchospasm. Circulation 1977; 56(Suppl III):198.
134. LeJemtel T, Hellman C, **Elkayam U**, Strom J, Blaufox D, Frishman W, Ribner H, Sonnenblick EH: Hemodynamics and renal response to oral hydralazine therapy in severe heart failure. Circulation 56(Suppl III):9, 1977.

BOOKS

1. **Elkayam U**, Gleicher N (editors): Cardiac Problems in pregnancy, 3rd Edition. Wiley-Liss, Inc. New York, New York, 1998
2. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors): Principles & Practice of Medical Therapy in Pregnancy, 3rd Edition. Appleton & Lange, Stamford, Connecticut, 1998
3. Gleicher N, Gall SP, Sibcu BM, **Elkayam U**, Galbraith RM, Sacto GE (editors): Principles of medical therapy in pregnancy, 2nd edition. Appleton & Lange, Connecticut, 1992
4. **Elkayam U**, Gleicher W (editors): Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. 2nd Edition. Alan R. Liss, New York, 1990
5. Gleicher N, **Elkayam U**, Galbraith RM, Gass S, Roux JF, Work BA, Wynn RS (editors): Principles of medical therapy in pregnancy. Plenum Publishing Corporation, New York, 1985
6. **Elkayam U**, Gleicher N (editors): Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. Alan R. Liss, New York, 1982

BOOK CHAPTERS

1. Frishman W, Silverman R, Strom J, **Elkayam U**: Adverse effects: choosing a beta-adrenoreceptor blocker. In: CLINICAL PHARMACOLOGY OF THE BETA-ADRENOCEPTOR BLOCKING DRUGS. Frishman W (editor). Appleton-Century Crofts, New York, 1980, p. 59.

2. Frishman W, Davis R, Strom J, **Elkayam U**, Stampfer M, Sonnenblick E: Pindolol (LB-46) therapy for supraventricular arrhythmia: a viable alternative in patients with bronchospasm. In: CLINICAL PHARMACOLOGY OF THE BETA-ADRENOCEPTOR BLOCKING DRUGS. Frishman W (editor). Appleton-Century Crofts, New York, 1980, p. 135.
3. Frishman W, Kostis J, Strom J, Hossler M, **Elkayam U**, Goldner S, Davis R, Weinstein J, Sonnenblick E: A comparison of pindolol and propranolol in treatment of patients with angina pectoris: the role of intrinsic sympathomimetic activity. In: CLINICAL PHARMACOLOGY OF THE BETA-ADRENOCEPTOR BLOCKING DRUGS. Frishman W (editor). Appleton-Century Crofts, New York, 1980, p. 145.
4. **Elkayam U**, Gleicher N: Cardiovascular physiology of pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 5-26.
5. Cobb T, Gleicher N, **Elkayam U**: Congenital heart disease and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 61-78.
6. Santora L, **Elkayam U**: Pericardial disorders and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 115-130.
7. Johnston DW, **Elkayam U**: Injective endocarditis in pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 131-140.
8. **Elkayam U**, Gleicher N: Primary pulmonary hypertension and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, 153-160.
9. Johnston DW, **Elkayam U**: Cardiac glycosides and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 281-288.
10. Gleicher N, **Elkayam U**: Birth control and abortion in the cardiac patient. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 305-317.
11. Gleicher N, **Elkayam U**: Intrauterine dysrhythmias. In: CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 535,564.

12. Gleicher N, **Elkayam U**: Intrauterine congestive heart failure. In: **CARDIAC PROBLEMS IN PREGNANCY: DIAGNOSIS AND MANAGEMENT OF MATERNAL AND FETAL DISEASE**. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1982, p. 565-578.
13. Frishman WH, Rotmensch HH, Charlap S, **Elkayam U**, Klein N: The use of B-adrenergic blocking agents during pregnancy. In: **CLINICAL PHARMACOLOGY OF THE B-ADRENORECEPTOR BLOCKING DRUGS**. 2nd Edition. Frishman WH (editor). Appleton-Century Crofts. Norwalk, Connecticut, 1984, p. 445-448.
14. Gleicher N, **Elkayam U**: Fertility control in the female patient with medical disease. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher et al (editors). Plenum Publishing Corporation, New York, 1985, p. 3-6.
15. **Elkayam U**, Gleicher N: Evaluation of the cardiac patient during pregnancy. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher N, et al (editors). Plenum Publishing Corporation, New York, 1985, p. 639-642.
16. Reid C, **Elkayam U**, Rahimtoola SH: Infective endocarditis in pregnancy. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher N, et al (editors). Plenum Publishing Corporation, New York, 1985, p. 671-679.
17. Dullet N, Santora L, **Elkayam U**: Diseases of the pericardium in pregnancy. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher N, et al (editors). Plenum Publishing Corporation, New York, 1985, p. 683-688.
18. Kumar A, **Elkayam U**: Hypertrophic cardiomyopathy in pregnancy. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher N, et al (editors). Plenum Publishing Corporation, New York, 1985, p. 695-696.
19. Rose J, Lee F, **Elkayam U**: Aneurysms of the aorta and its branches. In: **PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY**. Gleicher N et al (editors). Plenum Publishing Corporation, New York, 1985, p. 700-704.
20. **Elkayam U**, Gleicher N: Pregnancy in the patient with heart disease. In: **CURRENT THERAPY IN CARDIOVASCULAR DISEASE**. Fortuin NJ (editor). B.C. Decker, Inc., Toronto, Philadelphia, 1987, p. 301-305.
21. **Elkayam U**, Gleicher N: Hemodynamic and cardiac function during normal pregnancy and the puerperium. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 1-5.
22. **Elkayam U**, Gleicher N: Changes in cardiac findings during pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 31-38.
23. **Elkayam U**, Gleicher N: Diagnostic approaches to maternal heart disease during pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 41-45.

24. Lee W, Shah PK, Amin D, **Elkayam U**: Hemodynamic monitoring of cardiac patients during pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 47-70
25. **Elkayam U**, Cobb T, Gleicher N: Congenital heart disease and pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 73-98.
26. Kumar A, **Elkayam U**: Hypertrophic cardiomyopathy in pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 129-136.
27. **Elkayam U**, Santora L: Pericardial disorders in pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 137-151.
28. **Elkayam U**, Gleicher N: Primary pulmonary hypertension and pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 189-197.
29. Reid CL, **Elkayam U**, Rahimtoola SH: Infective endocarditis in pregnancy In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 199-211.
30. **Elkayam U**, Rose J, Jamison M: Arterial aneurysms and dissection during pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 215-229.
31. Moriguchi Mitani G, Steinberg I, Lien EJ, Harrison EC, **Elkayam U**: Pharmacokinetics of drugs in pregnancy and lactation. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd Edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 343-349.
32. Moriguchi Mitani G, Johnston WD, Steinberg I, Harrison EC, **Elkayam U**: Digitalis glycosides in pregnancy. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 417-427.
33. Gleicher N, **Elkayam U**: Fertility control in the cardiac patient: In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 453-460.
34. Gleicher N, **Elkayam U**: Fetal rate and rhythm disorders. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 723-748.
35. Gleicher N, **Elkayam U**: Intrauterine therapy of rhythm and rate disorders and heart failure. In: **CARDIAC PROBLEMS IN PREGNANCY**. 2nd edition. **Elkayam U**, Gleicher N (editors). Alan R. Liss, New York, 1990, p. 749-763.

36. Kulick D, **Elkayam U**: Central and renal hemodynamic effects of diltiazem in chronic heart failure. In: HEART FAILURE MECHANISMS AND MANAGEMENT. Lewis BS, Kimchi A (editors). Springer-Verlag, New York, 1991, p. 306-312.
37. **Elkayam U**: Pregnancy and cardiovascular disease. In: HEART DISEASE, 4th edition, Braunwald E (editor). W.B. Saunders Co, 1992, p. 1790-1809.
38. **Elkayam U**, Gleicher N: The evaluation of the cardiac patient during pregnancy. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 759-762.
39. Widerhorn J, Widerhorn ALM, **Elkayam U**: Cardiovascular pharmacotherapy during pregnancy and lactation. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 767-783.
40. Reid CL, **Elkayam U**, Rahimtoola SH: Infective endocarditis in pregnancy. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, 795-801.
41. Shotan A, Mehra A, **Elkayam U**: Myocarditis. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 802-805.
42. Mehra A, Shotan A, **Elkayam U**: Diseases of the pericardium. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 805-811.
43. **Elkayam U**, Ostrzega E, Shotan A: Peripartum cardiomyopathy. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 812-814.
44. Kumar A, **Elkayam U**: Hypertrophic cardiomyopathy. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 814-817.
45. **Elkayam U**, Shotan A: Aortic dissection. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 823-826.
46. Widerhorn J, Rahimtoola SH, **Elkayam U**: Cardiac rhythm disorders. In: PRINCIPLES OF MEDICAL THERAPY IN PREGNANCY. 2nd edition. Gleicher N, **Elkayam U**, Galbraith RM et al (editors). Appleton and Lange, 1992, p. 826-833.
47. Widerhorn J, Widerhorn ALM, **Elkayam U**: Cardiovascular drugs in pregnancy and lactation. In: CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. Singh BN, Dzau VJ, Vanhoutte PM, Woosley RJ (editors). Churchill Livingstone, New York 1994, p. 1143-1157.

48. **Elkayam U**: Organic nitrates - mechanisms of action and potential limitations. In: NITROGLYCERIN 8: BASICS, STANDARD AND ELECTIVE APPLICATIONS. H.C. Mehmel (editor). Walter de Gruyter, Berlin, New York 1996, pp. 75-87.
49. **Elkayam U**: Congestive heart failure. In: CONN'S CURRENT THERAPY. Rakel RE (editor). W.B. Saunders Co., Philadelphia, PA 1997, 288-294.
50. **Elkayam U**: Pregnancy and Cardiovascular Disease. In: HEART DISEASE, 5th Edition. Braunwald E (editor). W.B. Saunders Co., 1997, 1843-1864.
51. Ngo AAN, Frishman WH, **Elkayam U**: Cardiovascular Pharmacotherapy Considerations During Pregnancy and Lactation. In: CARDIOVASCULAR PHARMACOTHERAPEUTICS. Frishman WH, Sonnenblick EH (editors). McGraw-Hill, Inc., New York, New York 1996, 1309-1345.
52. **Elkayam U**, Vlachonassios K, Frishman W: Calcium channel blockers. In: HART FAILURE: SCIENTIFIC PRINCIPLES AND CLINICAL PRACTICE. Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS et al (editors), Churchill Livingstone, New York, 1997, 731-745.
53. **Elkayam U**, Gleicher N: Hemodynamics and cardiac function during normal pregnancy and the puerperium. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:3-19.
54. **Elkayam U**, Gleicher N: Cardiac evaluation during pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:23-32.
55. Warnes CA, **Elkayam U**: Congenital heart disease and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:39-53.
56. **Elkayam U**, Khan SS: Pregnancy in the patient with artificial heart valve. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:61-78.
57. Shotan A, Bokhari SWH, **Elkayam U**: Myocarditis and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:79-85.
58. Lang RM, Lampert MB, Poppas A, Hameed A, **Elkayam U**: Peripartur cardiomyopathy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:87-100.
59. **Elkayam U**, Dave R: Hypertrophic cardiomyopathy and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:101-109.

60. Mendelson MA, **Elkayam U**: Pericardial disorders and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:111-120.
61. Roth A, **Elkayam U**: Acute myocardial infarction and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:131-153.
62. **Elkayam U**, Dave R, Bokhari SWH: Primary pulmonary hypertension and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:183-190.
63. Ebrahimi R, Leung CY, **Elkayam U**, Reid CL: Infective Endocarditis. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:191-198.
64. **Elkayam U**, Hameed A: Vascular dissections and aneurysms during pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:201-209.
65. **Elkayam U**, Ostrzega E, Shotan A, Mehra A: Marfan syndrome and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:211-221.
66. **Elkayam U**, Hameed A: Takayasu's arteritis and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:237-245.
67. Steinberg I, Mitani GM, Harrison EC, **Elkayam U**: Pharmacokinetics of drugs in pregnancy and lactation. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:341-349.
68. Hurst AK, Hoffman K, Frishman WH, **Elkayam U**: The use of β -adrenergic blocking agents in pregnancy and lactation. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:357-372.
69. Shotan A, Hurst AK, Widerhorn J, Frenkel Y, **Elkayam U**: Antiarrhythmic drugs during pregnancy and lactation. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:373-390.
70. Shotan A, Widerhorn J, Hurst AK, **Elkayam U**: Angiotensin-converting enzyme inhibitors and pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:399-406.
71. Steinberg I, Mitani GM, Harrison EC, **Elkayam U**: Digitalis glycosides in pregnancy. In: CARDIAC PROBLEMS IN PREGNANCY, 3rd Edition. **Elkayam U**, Gleicher N (editors). Wiley-Liss, Inc., New York, 1998:419-435.
72. Gleicher N, **Elkayam U**: Principles of medical care. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr.,

Elkayam U, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:12-15.

73. **Elkayam U**, Gleicher N: Evaluating the cardiac patient. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:908-911.
74. Ebrahimi R, Leung CY, **Elkayam U**, Reid CL: Infective endocarditis. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:942-946.
75. Mehra AO, Shotan A, **Elkayam U**: Diseases of the pericardium. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:949-957.
76. **Elkayam U**, Dave R: Hypertrophic cardiomyopathy and pregnancy. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:965-968.
77. **Elkayam U**, Karaalp IS, Wani O, Hameed AB: Aortic dissection. In: PRINCIPLES & PRACTICE OF MEDICAL THERAPY IN PREGNANCY, 3rd Edition. Gleicher N, Buttino L, Jr., **Elkayam U**, Evans MI, Galbraith RM, Gall SA, Sibai BM (editors). Appleton & Lange, Connecticut, 1998:973-975.
78. **Elkayam U**: Pregnancy and Cardiovascular Disease. In: HEART DISEASE: A TEXTBOOK OF CARDIOVASCULAR MEDICINE, 6th Edition. Braunwald E, Zipes, DP, Libby P (editors). Harcourt Health Sciences Co., Philadelphia, PA, 2001.
79. Hameed A, **Elkayam U**: Peripartum Cardiomyopathy. In: CARDIOLOGY. DiMarco J, Crawford M (editors). Harcourt Health Sciences. London, UK, October 2000
80. Akhter MW, Hamed A, **Elkayam U**: Peripartum Cardiomyopathy. In CARDIOLOGY DiMarco, C. 2nd ed. Philadelphia: Mosby 2003
81. **Elkayam U**. Pregnancy and cardiovascular disease. In HEART DISEASE: A TEXTBOOK OF CARDIOVASCULAR MEDICINE, 7TH edition. Zipes DP, Libby P, Bonow W, Braunwald E (editors) Harcourt Health Sciences Co., Philadelphia, PA, 2004
82. **Elkayam U**, Bitar F, Kiramijyan S, Hatamizadeh P, Binkley PE, Lerce CE. Vasodilators in Congestive Heart Failure 3rd Edition. Hosenpud JD, Greenberg BH, Lippincott Williams & Wilkins Philadelphia 2007;489-509.
83. Naqvi TZ, Lee MS, **Elkayam U**: Pregnancy and the heart. In Dynamic echocardiography, 2nd edition. American Society of echocardiography. Elsevier, in Press.

84. Havakuk O, **Elkayam U**: Hemodynamics and cardiac function. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
85. **Elkayam U**: Cardiovascular evaluation during pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
86. Colletti P, **Elkayam U**. Cardiovascular imaging in the pregnant patient. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
87. **Elkayam U**: Native valvular heart disease and pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
88. **Elkayam U**. Pregnancy in the patient with prosthetic heart valves. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
89. Goland S, **Elkayam U**: Peripartum cardiomyopathy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
90. Van Hagen IM, **Elkayam U**, Goland S, Roos-Hesselink JW: Hypertrophic cardiomyopathy and pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
91. **Elkayam U**, Havakuk O: Acute myocardial infarction and pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
92. Spears D, **Elkayam U**: Cardiac arrhythmias and pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
93. Goland S, **Elkayam U**: Marfan syndrome and pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
94. Mehra A, Muadi G, Reddy P, **Elkayam U**: Catheter based interventions in women with heart disease during pregnancy. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.
95. Pieper PG, **Elkayam U**, Eskandar J, Ruys TPE. In Cardiac problems in pregnancy, 4th edition. **Elkayam U** editor, Wiley Blackwell 2020.

LETTERS TO THE EDITOR

1. **Elkayam U**: Paradoxical septal motion in right ventricular infarction. Am J Cardiol 45:906, 1980.
2. **Elkayam U**: Heart rate response to oral prazosin in patients with chronic congestive heart failure. Am J Cardiol 46:704, 1980.
3. **Elkayam U**: Mitral stenosis and coronary angiography. Am J Cardiol 49:257, 1982.
4. **Elkayam U**, Gleicher N: Cardiac arrhythmias during pregnancy. JAMA 254:1511, 1985.

5. **Elkayam U**: Safety of nifedipine in severe congestive heart failure. *Am J Cardiol* 57:895, 1986.
6. **Elkayam U**, Gleicher N: Anticoagulation in pregnant women with an artificial heart valve. *N Engl J Med* 316:1663-1664, 1987.
7. Rubin N, Widerhorn J, **Elkayam U**: Nitroglycerin tolerance. *N Engl J Med* 318:120, 1988.
8. Widerhorn J, Rubin JN, **Elkayam U**: Antiarrhythmic drugs during pregnancy. *Cardio* (October) p. 104-118, 1988.
9. **Elkayam U**: Holter monitoring versus treadmill exercise test in the detection of myocardial ischemia. *Am J Cardiol* 63:261, 1989.
10. **Elkayam U**, Letter Regarding Article by Wang et al, "Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine" *Circulation* 111:e182-3, Apr 2005.